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INTRODUCTION 
Renal cell carcinoma or renal adenocarcinoma represents an intriguing 
problem in tumor behaviour and tumor cell biology. This type of 
carcinoma is a disease of older adults, the median age at diagnosis 
being about 55 years. It may remain asymptomatic until relatively late 
in its natural history. Also one third of the patients is known not to 
present with urological symptoms which can result in a delayed 
diagnosis. About 30% of patients have overt metastases at the time of 
diagnosis (1, 2, 3). In addition, the clinical course and prognosis of 
metastatic renal cell carcinoma is extremely variable and 
unpredictable, although generally poor with a median survival time of 
Θ-10 months after the time of diagnosis (1). Spontaneous regression of 
metastases has been reported, mostly concerning lung metastases 
disappearing after nephrectomy (4). The incidence of spontaneous 
regression, however, is very rare and at the moment it is impossible 
to identify such patients in an early stage of the disease. A special 
entity in metastatic renal cell carcinoma is a primary tumor with a 
solitary metastasis, which has an identical prognosis as 
non-metastasized renal cell carcinoma when treated aggressively (5). 
One of the phenomena suspected to be responsable for the capricious 
behaviour of the tumor ia a high degree of immunological host-tumor 
interaction (6). However our actual knowledge about renal cell tumor 
biology is still fragmentated, making a strategic approach in therapy 
very difficult. 
At the moment it appears that the limits of therapeutical modalities 
for localized disease have been reached in radical nephrectomy (7). It 
is known that surgical treatment, performed in an early stage of 
disease, is the only approach that can lead to a cure in renal cell 
carcinoma. Unfortunately one third of these patients prove to have 
clinical imperceptible metastases at the time of surgery rendering the 
prognosis for these patients negligible with a 5 year survival of 0-8% 
(2, 7). 
Logically, the identical surgical approach in clinically advanced 
cases does not guarantee a definite cure. Nor does pre- or 
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postoperative combination with irradiation, chemotherapy, hormonal 
therapy or immunotherapy improve the prognosis so far (B, 9, 10, 11, 
12). 
In light of this knowledge one can conclude that progression in the 
treatment of renal cell carcinoma is to be made by 
1) development of new techniques for earlier diagnosis, 
2) advances in systemic therapy, and 
3) a better understanding of cell biological properties and clinical 
behaviour of the tumor. 
This thesis has been written in order to shed some light on aspects of 
the biological, biochemical and histochemical properties of renal cell 
carcinoma. For this purpose a spontaneous rat renal cell tumor (13) 
and several renal cell carcinoma xenografts in nude mice (14) were 
studied. Routine techniques such as light microscopy and electron 
microscopy as well as flow cytometric DNA measurements, determination 
of intermediate filament expression, activated oncogene analysis and 
growth studies in the double layer soft agar culture system were 
performed. 
In order to be able to compare the results of these studies with the 
results obtained in human tumors, also flow cytometry and oncogene 
studies were performed on primary human renal cell carcinomas. 
A brief inventory on what is known about renal cell carcinoma, its 
clinical behaviour, its prognostic factors, and its histological and 
biological properties is made below. 
RENAL CELL CARCINOMA 
Epidemiology 
Malignant renal cell carcinomas account for 3!· of all cancers in human 
and renal adenocarcinomas constitute 85% of all renal tumors (15). The 
median age at diagnosis of renal cell carcinoma is 55 years (16) and 
is two or three times more common in men than in women (17). The 
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incidence of renal cell carcinoeas is highest in the Nordic countries 
and lowest in the Orientals (18). 
Clinical presentation 
About 70% of the patients with a renal cell carcinoma present with 
urological symptoms such as hematuria, flank pain or a palpable mass. 
A combination of these three sywptoms, called "the classical triad", 
occurs only in 9% of all cases (7, 19). 
Ten percent of all patients with renal cell carcinoma present with 
primary symptoms as a result of metastases in lungs, bones or brain 
(7). In turn 6% of patients renal cell carcinoma is accidentally 
encountered in the course of a diagnostic procedure for other reasons 
(20). Renal cell carcinoma is frequently accompanied by aspecific 
signs of malignancy including weightloss, fatigue and gastrointestinal 
symptoms (255·), fever, secondary to tumor necrosis or tumor pyrogens 
(20%), anemia (30%) and a raised E.S.R. (erythrocyte sedimentation 
rate) (39Й) (21). 
Also paraneoplastic syndroms such as erythrocytosis (10%) and 
hypercalcemia (5%), as a result of bone metastases or ectopic or 
primary hyperparathyroidism are seen (21). 
In 15% of the patients the so called Stauffer syndrome is found. This 
is represented by a hepatic dysfunction (detected as elevated serum 
levels of indirect bilirubin, alpha2 globulin and alkaline phosphatase 
combined with hypoprothrombinenia) in absence of metastases, which 
resolves spontaneously after nephrectomy (22). 
In addition renal cell carcinoma can present with a variety of 
symptomatology such as vaginal bleeding secondary to vaginal 
metastasis, priaprism as a result of penile metastases, breast masses 
secondary to breast metastases, varicocele following obstruction of 
the spermatic or ovarian vein by tunor mass or several syndroms of 
ectopic hormone production (21, 31). 
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Metastatic behaviour 
The metastatic route of renal cell carcinoma is threefold (21), 
lymphogenous to regional and juxtaregional nodes, 
2) lymphohematogenous, and 
3) hematogenous. 
The lymphogenous metastases affect mainly the renal hilar lymphactics 
and the regional, paracaval, paraaortal and parailiacal lymph nodes. 
The lymphohematogenous pathway follows the thoracic duct into the 
supraclavicular venous angle. 
The hematogenous metastases spread mostly directly via the renal vein 
and via pararenal and paravertebral anastomoses. Also retrograde 
spread via the spermatic or ovarian veins is possible (27). 
This phenomenon may account for the odd clinical presentations 
mentioned above. 
When metastasized at the time of diagnosis, renal cell carcinoma shows 
in 70% metastases limited to one organ, usually the lung (45%) or the 
bone (22%) (7, 23). Autopsy, performed on patients with renal cell 
carcinoma, shows in 81-95% of cases multiple metastases. The incidence 
of involvement of different sites is noted as follows: lung (67-76%), 
lymphnodes (40-66%), bones (mostly lytic of character) (42%), liver 
(41%), contralateral kidney (23%), ipsilateral adrenal (17%) 
and contralateral adrenal or brain (11%) (24, 25, 26). 
To identify the prognosis of the subsets of renal cell carcinomas with 
or without metastases, many efforts were made to relate clinical 
staging and cellular, histological and biochemical characteristics to 
prognosis. 
Classification of anatomical extent 
To express and determine the relative value of the anatomic extent of 
renal cell carcinoma two methods are presently in use. The first is 
the Robson classification scheme (2), a major step forward at the time 
of its presentation in 1969, made by establishing the basic principles 
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for a delineation of the anatomic extent of the disease. The second 
scheme is the ΤNM staging system as proposed by the U.I.C.C. (2Θ) in 
197Θ, which more explicitely defines the anatomic extent of the 
disease including venous involvement. 
Several studies (7, 21, 29, 30) confirmed the stage related prognosis 
which means that an advanced tumor stage, local tumor invasion and 
invasion of vena renalis or cava and even regional lymph node invasion 
are unfavourable signs. 
Histopathological classification 
Renal cell carcinoma has been proposed to originate from the proximal 
tubular epithelium of the nephron (21). 
Macroscopically, renal cell carcinomas are solid tumors of a yellow to 
grey color depending on their lipid content. In large tumors often 
areas of tumor cell necrosis are found. There is no preference for 
localization in certain areas of the kidney (26). 
Microscopically, tumor structures vary from tubular, papillary, cystic 
to a solid and anaplastic character. The histological cell type 
patterns are to be classified in four subsets based on cytoplasmic 
properties (26): 
1) clear cell tumors (23%) consisting of cells containing large 
amounts of lipids and glycogen (34). 
2) granular cell tumors (13%) containing cells with granular cytoplasm 
as a result of abundant, mostly abnormal, mitochondria and cellular 
organelles (34). 
3) mixed type tumors (46%) containing both clear cells and granular 
cells. 
4) sarcomatoid or spindle cell tumors (14%). 
Statistically clear cell tumors appear to have a somewhat favourable 
prognosis as compared to granular and mixed type tumors, but this is 
not a consistant finding in literature (3, 32). An overall 3 year 
survival rate is reported to be 30%. Spindle cell tumors, however, 
have a significantly worse prognosis showing a 3 year survival rate of 
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23» О ) . 
The histological grading vanes from highly differentiated (Gl, 285«), 
via intermediate (G2, 32SÍ) to undifferentiated (G3, 40Й) (15). The 
significance of the histological degree of differentation for the 
prognosis of renal cell carcinoma is generally recognized (29, 30). 
This means that roughly grade I tumors of the primarily 
non-metastasized renal cell carcinoma clearly show the best prognosis 
(30, 32). 
In the German literature a combination of staging and grading is 
proposed by Hermanek et al. (33), identifying groups with survival 
curves that are clearly distinguishable from each other (30). 
Ultrastructural grading is found to add little to light microscopic 
grading; neither could adenomas be distinguished from 
adenocarcinomas. Ultrastructural analysis is most helpful, however, in 
tumor classification. Also ultrastructural similarities between tumor 
cells and cells of the proximal convoluted tubule are encountered 
(34). Moreover several features of renal cell carcinoma such as lipid 
and glycogen content, which disappear upon routine histological 
processing, are easily identifiable (34). 
Nuclear grading is based on the impression that distinctly larger 
nuclei in renal cell carcinoma are an expression of an aneuploid state 
and therefore represent a morphologic sign of biologic anaplasia. For 
this purpose the relative sizes of the nuclei of the cancer cells are 
categorized. If more than 5% of the entire nuclear content shows a 
variation factor in the nuclear area surface greater than two, the 
survival rates of patients in the same atage of disease (according to 
Robson) (2) differ significantly and it is suggested that foci of 
cells with larger nuclei in primary renal cell carcinoma can be 
interpreted as the morphologic manifestation of tumor agressiveness. 
As such, nuclear grading has been reported to be of dominant 
prognostic value in supplement to the Robson staging system (35, 36). 
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Marker studies 
Recently monoclonal antibodies detecting cell surface antigens, 
expressed in distinct domains of the normal adult human nephron, have 
been identified (37). They are supposed to be valuable reagents for 
the definition of cellular origins and subsets of renal cell carcinoma 
in relation to prognosis and therapy. In analogy to bladder carcinoma, 
renal cell carcinomas have been examined for the presence of A.B.O. 
(H) blood group antigens, T-antigen and C.E.A. (carcinoembryonic 
antigen), but no valuable results were established (38). 
The latest developments in renal cell tumor characterization concern 
flow cytometric DNA content analysis, the study of cytoskeletal 
structures and activated oncogene identification. 
Flow cytometric analysis allows us to study factors such as the DNA 
content and heterogeneity of a certain tumor by using a two parameter 
analysis (39). Also the ploidy of a certain specific tumor fraction 
can be determined. The DNA content may be a very important parameter 
in diagnostic pathology, as a change in DNA content may be one of the 
main characteristics of malignant transformation or progression and 
may be of prognostic value in renal cell carcinoma (40). 
Studies on the composition of the cytoskeletal structures in tumors 
may provide information about their cell composition and histogenesis. 
The cytoskeleton consists of a fibrous matrix of proteins spanning the 
cytoplasm between nucleus and plasma-membrane and may have important 
functions in many vital processes of the cell. One group of proteins 
has been shown to be of particular importance for the characterization 
of different tumors and tissue types. These are the so-called 
intermediate sized filaments (I.F.; 7-11 nm diameter) represented by 
five different protein types with a tissue specific distribution 
(41). In tissues most cells express only one charactenstical I.F. 
protein. Specific I.F. protein expression is generally preserved upon 
neoplastic transformation (42). 
I.F. expression in renal cell carcinoma shows interesting aspects, in 
that a coexpreasion is seen of two I.F. proteins, i.e. cytokeratin, a 
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marker for epithelial cells, and vimentin, which is predominantly 
found in mesenchymal cells (43, 44, 43). In contrast, this 
coexpression is normally not found in the mature human kidney. In the 
proximal tubular cells of the nephron only cytokeratin is 
encountered. In the fetal stage however, the embryonal mesenchyme 
expresses vimentm suggesting that some tumor cella reexpress their 
embryonal I.F. pattern (44). 
The correlation of these findings with the biological behaviour of 
renal cell carcinoma may lead to a better understanding of the 
characteristics of renal cell tumors and their subfractions. 
Recently another challenging field in the progressing knowledge of 
tumongenesis has emerged in the form of the discovery, that common 
molecular mechanisms may be responsible for the origin of cancer. In 
the normal cell these mechanisms are regulated by genes called 
proto-oncoqenes. They fullfill regulatory functions in cell growth and 
differentiation. By means of somatic mutations (either spontaneous or 
induced by environmental factors) they can be abnormally activated and 
thus turn into oncogenes, capable of deregulating the cell, for 
instance in favour of cell proliferation. 
Up to this moment more than fourty oncogenes have been characterized. 
Mainly based upon localization of gene products within the cell the 
proto-oncogenes are divided in categories (46). One category consists 
of so called nuclear oncogenes and one of cytoplasmic oncogenes (46). 
The nuclear group is the smallest one in which among others the 
proto-oncogenes c-myc, c-myb and p53 are classified. These genes tend 
to have immortalization abilities and are generally weak in inducing 
anchorage independence of fibroblasts in culture. Their encoded 
proteins are usually bound to nuclear structures. In their action a 
deregulation of transcription seems to be involved (47). The encoded 
proteins of c-myc and c-myb are structurally homologous (48). p33 is a 
phosphoprotein that is overexpressed in transformed cells (49). The 
expression of p33 is apparently necessary for maintaining cells in a 
transformed state in certain cases (30). 
The larger cytoplasmic group is characterized by localization of their 
gene products in the cytoplasm. These oncogenes are thought to be 
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involved in the event of transformation and anchorage independence of 
fibroblasts in culture. Their mode of functioning seems to be rather 
divergent (46). Members of this group are for instance the family of 
ras genes, the fes oncogene and the abl oncogene. Their activation can 
be the result of a mutation of the structure of their encoded 
protein. (For instance, the p21 ras protein can be activated by a 
point mutation, which affects the GTP-ase binding properties.) 
The p21 protein of c-ras is localized at the inner surface of the cell 
membrane and has been shown to reveal homology to the G-proteins, 
which are known to function as signal transducers of cell surface 
receptors (51). The c-fea and the c-abl oncogene belong to a group 
that is characterized by a tyrosine specific protein kinase activity. 
In this group the functional analogy is more obscure, however, some 
might encode receptor-like proteins. 
The analysis of activated oncogene expression in renal cell carcinoma 
is therefore important as a fundamental approach that may lead to a 
better understanding of tumorigenesis. Moreover, this analysis could 
possibly be of diagnostic value. 
Schematically the analysis of the structure and expression of 
proto-oncogenes is performed as follows: 
Tissue sample/cultured cells 
DNA-isolation mRNA isolation 
restriction enzyme 
digestion/gel electrophoresis 
Southern blotting 
gel electrophoresis 
restriction-map 
of (proto-)oncogene 
Northern blotting 
Hybridization with 
radioactivily (32p) — 
labeled oncogene probes 
level of transcription/ 
length of transcript 
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The study of (proto-)oncogenes in relation to renal cell carcinomas 
reported in this thesis is confined to the experiments outlined 
so far. One should realize that this is only the onset of a research 
program for a team of molecular oncologists. Once a typical expression 
pattern of one or more genes for a certain type of cancer is 
established, one should discriminate between expression at an abnormal 
level, and synthesis of an altered gene product. In both cases one 
wants to know the causal relationship, if any, between the observation 
ana the development of the cancer. In the former case the research 
will be aimed at the elucidation of the genetic sequences responsible 
for the abnormal expression and of the factors that in their turn act 
as effectors in the regulation of these genes. In the latter case the 
nature of the modification should be studied in an attempt to 
understand the malignant properties of the oncogene. The history of 
medicine, although loaded with empirical therapies, is witness to the 
fact that other new insights eventually lead to substantial 
improvement of the treatment of patients. This view has inspired our 
research and is the justification of molecular oncology. 
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ABSTRACT 
The rat renal cell carcinoma system as described by deVere White and 
Olsson in 1980, is used widely as a model for its human counterpart. 
The tumor arose spontaneously in a male Wistar Lewis rat and its 
behaviour has been shown stable during multiple passages. We have 
compared this tumor with the human renal cell carcinoma using a 
multidisciplinary approach. Light microscopy and electron microscopy 
showed a great resemblance of this rat tumor to a human renal cell 
carcinoma of the clear cell type with the ultrastructural presence of 
desmosomes. With the use of tissue specific antibodies against 
intermediate filament proteins it could be shown that their expression 
is comparable to human renal cell carcinoma, i.e. coexpression of 
vimentin and different cytokeratins in the tumor cells. The cells 
could also be shown to contain cytokeratin 18. An aneuploid cell 
population in the tumor, expressing both vimentin and keratin, could 
be characterized by DNA flow cytometry in double labeling 
experiments. Comparison of normal and malignant rat kidney tissue by 
Northern blot analysis revealed increased levels of vimentin mRNA. In 
the double layer soft agar human tumor cloning system rat renal cell 
tumors showed a positive growth capacity. In conclusion this tumor 
model seems to have several histological and biological properties in 
common with the human renal tumor. 
INTRODUCTION 
Metastatic renal cell carcinoma in man has a mortality rate of about 
10% in the first year and virtually no five year survivals. For this 
reason one is reluctant to treat these patients with experimental 
cytotoxic chemotherapy. This therapy may, in a number of cases, not 
only fail to induce an increased survival time, but may even decrease 
the quality of life. 
Therefore it should be preferred to test experimental treatment 
protocols in animal models. For the extrapolation of results that are 
obtained in an animal model to the human situation, the animal model 
system should closely resemble the human renal cell carcinoma. 
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deVere White and Olsson have described a rat renal adenocarcinoma 
model system, that has been used in several studies, amongst which 
chemosensitivity tests (deVere White et al., 19B0, 1982 and 19Θ3). 
This rat renal cell tumor arose spontaneously in the kidney of a male 
Wistar Lewis rat. It has been maintained by tranplantation in the 
flank of syngeneic rats and has shown more or less predictable growth 
characteristics over several years. 
In order to be able and use the rat renal cell tumor as a model system 
for human renal cell carcinoma we analized the animal tumor in a 
multidisciplinary approach and compared its cell biological properties 
with those of human renal cell carcinomas. 
MATERIALS AND METHODS 
The rat renal tumor was maintained as follows (deVere White et al., 
1980): Donor animals with large tumor nodules (3-6 cm in diameter) 
were anesthetized with ether. Under sterile conditions, the tumor was 
dissected en bloc. The normal tissue was excised from the tumor nodule 
and the tumor tissue cut into pieces of about 0.06 gr. 
In recipient animals an 0.5 cm incision was made in the flank and the 
tumor fragment was implanted subcutaneously. The average tumor take in 
this way, was more than 90% and the tumor did not metastasize from 
this site. Wistar Lewis rats from 0LAC (England) were used for further 
maintenance. We therefore evaluated the original tumor as well as the 
tumor in the English Wistar Lewis rats. In these latter animals the 
tumor could easily be kept and preserved the same macroscopic 
characteristics as in the original Wistar Lewis rats. 
Histology: Tissue material of a representative part of the tumor was 
prepared for routine histological examination using hematoxylin and 
eosin (H. and E.) and periodic acid schiff (P.A.S.) staining. 
Histological classification was in accordance to the human renal cell 
tumor classification (Bennington and Beckwith, 1975). 
Electron microscopy: The tumors were cut into small pieces and 
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fixed in a cacodylate buffered mixture of glutaraldehyde and 
paraformaldehyde. Following postfixation in osmic acid and dehydration 
in graded ethanol they were embedded in Epon. Double contrasted 
ultrathin sections were examined in a Philips EM 300. 
Immunohistochemistry; 5-7 Micron thick frozen sections of the rat 
renal cell carcinoma, snap-frozen in liquid nitrogen were fixed in 
methanol at -20иС for 5 m m . and thereafter dipped in aceton at room 
temperature. The indirect inmunofluorescence technique was performed 
as described before (Ramaekers et al., 1983a). 
The following antisera were used in this study : 1 ) An affinity 
purified rabbit antiserum to human skin keratins for the detection of 
the epithelial nature of the tumor. 2) An affinity purified rabbit 
antiserum to bovine lens vimentin, the intermediate filament protein 
of mesenchymal cells. 3) A monoclonal antibody to cytokeratin 18 (RGE 
53) specific for glandular epithelial cells (Ramaekers et al., 1983). 
FCM analysis; cell analyses were performed using a cytofluorograph 
50 OH (Ortho Instruments, Westwood, MA) as described before (Feitz et 
al., 19 6а). All data were stored in correlated (list) mode on a PDP 
11/34 computer (Digital, Marlboro, MA) for subsequent data analysis. 
The normal human DNA index in our laboratory is 2.65 to 2.75 times the 
fluorescense intensity of chicken red blood cells (CROC) (Hiddeman et 
al., 1984) Cell cycle analysis was done as described by Baisch et al. 
(1975). As a control, cells incubated only with an FITC-conjugated 
second antibody were analyzed. 
Human tumor clonoqenic culture system (H.T.C.5.): For the detection of 
the growth potential of tumor cells in the soft agar double layer cell 
culture, the culture system as described by Hamburger (1977) was 
used. Tissue selected for this test was processed according to Salmon 
et al. (1978). The cells were cultured immediately after preparation 
of the single cell suspension and growth potential was quantified 
using the Omnicon FAS II automated colony counter (Milton Roy Inc., 
Rochester, New York, USA) (Herman et al., 1983). For dynamic colony 
growth evaluation a "Temporal Growth Pattern" (T.G.P.) was used which 
gives a description of the growth over a certain period of time. The 
b n t e n a that had to be met for these evaluations are described by 
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Feitz et al. (1986b) and Verheijen et al. (1985). Also a plating 
efficiency can be calculated by the formula: 
(number of colonies χ 100). 
amount of cells/disk 
Northern and Southern blot analysis; Expression of vimentin at the 
mRNA level, using actin mRNA as a standard, was evaluated using pViml 
and pActl as probes (Dodemont et al., 1982). Preparation of the DNA 
probe and nick translation (Rigby et al., 1977) was performed as 
described before (Schalken et al., 1985). Primer extension reactions 
were according to Messing and co-workers (Messing et al., 1982). The 
specific activity of the probes used in the hybridization studies was 
(2-5) χ 10^ cpm/^g. Agarose gel electrophoresis, Southern blot 
(Southern, 1975) and hybridization analysis was performed as described 
before (Schalken et al., 1985). 
Total cellular RNA was isolated according to the procedure described 
by Auffray and Rougeon (1980). Upon poly(A) selection by 
oligo(dT)-cellulose chromatography, RNA was dissolved in sodium 
phosphate buffer (10 mM, pH 7.0), which containing 50Ä DMSO and 1 M 
glyoxal, and heated to 50° С for 1 h. RNA was size fractionated by 
agarose gel electrophoresis (1.0% agarose gel) and transferred to 
Hybond N (Amersham) for hybridization analysis as described before 
(Steenbergh et al., 1984). 
RESULTS 
Transplantation in vivo 
The rat renal tumor model system described in this paper showed a 90% 
acceptance rate after subcutaneous transplantation of tumor pieces 
during ten passages. No differences were found between the original 
Wistar Lewis rat and the rats finally used in this study. 
The tumors showed a reproducable growth curve as shown in Fig. I, 
which illustrates an example of a growth curve in vivo of the 
f^urthpassage in three different rats. 
T'ie mean growth in these three tumors is 9,1 cm5 (longeet diameter 
-32-
LxBxH 
12' 
11 
10-
9· 
β' 
1-
6 
S 
4-
3 
2· 
1 
0 k б 12 Í6 Ä 2A 28 3'2 DAYS 
Fig I; Example of in vivo growth curve of tumor nodules in three 
different rats during the fourth passage. Tumor volumes are calculated 
according to the formula described by Jamk et al. (1978): length χ 
width χ height χ (0,52x10-3) (symbol:LxBxH). 
Fig II; Immunohistochemistry and electron microscopy of the rat renal 
cell tumor, (a) Positive reaction for cytokeratin and (b) vimentin 
polyclonal rabbit antiserum in the tumor cells (x 230). (c) Low 
magnification of glandularlike formation of epithelioidly arranged 
electron dense tumor cells with few light cells interspersed. Note 
mitotic figure in light cell (arrow), (x 2000). Asterisks indicate 
glycogen areas, (d) Part of two electron-dense tumor cells with 
adherence-like junctions and intermediate-sized filaments. Asterisks 
indicate glycogen. Arrow points to incomplete basal lamina, (x 
18500). (e) Detail of an electron-dense and electron-light tumor cell 
with a small desmosome. At open arrows intermediate-sized filaments 
are shown, (x 24000). (f) Two electron-light tumor cells with 
desmosomes and intermediate-sized filaments (open arrows); black 
arrows indicate glycogen particles.(χ 29500). 
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versus height and width χ 0,52x10-3) (Запік et al., 197 ) at day 28. 
Light microscopy 
The rat renal cell carcinoma was composed of solid tumor areas 
containing cells with a large cytoplasm of varying size. The cytoplasm 
of the cells was strongly eosinophilic and contained multiple 
vacuoles. Nuclei mostly excentncally localized and round to ovally 
shaped, showed often invaginations and contained one or more 
macronucleoli of an irregular or round shape. Extensions, part of 
which showed an atypical appearence, could be observed. Between the 
tumor cells solid areas of spindle-formed cells with oval nuclei and 
an eosinophilic granular cytoplasm were seen. The histological 
appearance fitted well with that of a clear cell type Grawitz tumor 
(renal cell carcinoma). 
Electron Microscopy 
The tumor mass was composed of clustered electron-dense cells. 
Electron-light cells were also found interspersed in between the dark 
cells (Fig. H e ) . Generally the nuclei contained several nucleoli. 
Incomplete basal laminae surrounded islets of mainly dark tumor 
cells. Glandular-like formations with lumina were observed, too. 
Mostly, smooth cell membranes were in close contact showing small 
desmosomes at several places and few fascia adherens-like junctions 
(Fig. lid). The organelles were well developed and few bundles of 
intermediate-sized filaments were present. 
Apart from some lysosomes, small-sized next large lipid droplets as 
well as electron-lucent vacuoles were always observed. Most strikingly 
was the presence of glycogen particles in varying amounts. Compared to 
the dark tumor cells the light cells were irregularly shaped, showing 
long projections. Junctional complexes were present between both types 
of cells (Fig. lie, f). Generally the rough endoplasmatic reticulum 
appeared to be more abundant in these cells and was arranged in 
whorl-like patterns. Distinct Golgi areas and intermediate-sized 
filaments were observed. The interstitium with fibroblasts consisted 
of collagenous fibrils and amorphous electron-dense plaques randomly 
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distributed. Macrophages were frequently found enclosing the 
peripheral localized tumor cells. 
Ultrastructurally the same tumor cell characteristics were found in 
both the American as well as in the English strain of rats. 
Immunohistochemistry 
It has recently been described by several investigators (Herman et 
al., 1983, Holthofer et al., 1983, Feitz et al., 1986a, b) that human 
renal cell carcinomas express both the epithelial and the mesenchymal 
type of intermediate filament proteins. Rabbit antisera to cytokeratin 
and vimentin, respectively, have been shown to react with such 
tumors. These antibodies did also stain both types of intermediate 
filament proteins in the rat renal cell tumor (Fig. II a, b), in both 
the clear cell and the granular cell part. Using a monoclonal antibody 
to cytokeratin 18 (RGE 53) coexpression of this adenocarcinoma marker 
and vimentin in tumor cell areas was clearly demonstrated. Therefore, 
these results show that, as far as intermediate filament expression is 
concerned, this rat renal cell tumor model is completely comparable to 
the human renal cell tumor. 
Flow cytometric DNA analysis 
The flow cytometric DNA analysis showed the presence of a mixture of 
two cell populations, one with a diploid and one with an aneuploid DNA 
content (Fig. Π Ι Α ) . In order to characterize these two cell 
populations, the two parameter flowcytometric technique with propidium 
jodide (P.I.), for the quantitation of DNA and labeling for vimentin 
or cytokeratin was used.Vimentin proved to be present both in the 
aneuploid tumor cells as well as in diploid cells (Fig. H I B ) . 
Cytokeratin was expressed only in the aneuploid tumor cells (Fig. 
UI C ) . The specific labeling of the tumor cells with the cytokeratin 
antibody allowed determination of the proliferative fractions of the 
neoplasm without any disturbance of the stromal component. The 
cytokinetic results for the aneuploid cells indicate an S-fraction of 
about 20» and a G2+M fraction of about IBS (n=4) (Fig. H I D ) . The 
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Fig 3 : Example of a two-parameter flow cytometric (FCM) analysis of a 
rat renal cell tumor using the cytokeratin antibody pKer and the 
vimentin antibody pVim in addition to DNA-staining with PI. (A) 
One-dimensional FCM DNA pattern of the cell suspension stained only 
with PI. (B) A two-dimensional projection of the DNA content and the 
vimentin content of the rat tumor. (C) A two-dimensional projection of 
the DNA content (as PI fluorescence) and the cytokeratin content (as 
FITC fluorescence) from the same cell suspension as shown in A. Note 
that the tumor fraction is cytokeratin- and vimentin-positive. (D) DNA 
histogram of the cytokeratin-positive cells, present in the cell 
suspension. The cell cycle parameters of the tumor cell suspension are 
indicated in the upper right corner. 
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distribution of normal rat kidney cells was G1= 82%, S= 5.6Й and G2+M= 
12.4Й. 
Northern and Southern blot analysis 
Analysis of vimentin expression in rat renal tumors and normal rat 
kidney tissue at the mRNA level was performed using pViml as a 
molecular probe. Actin expression was used as a standard using pActl 
as a probe. It was shown that there was a threefold increase of 
vimentin expression in the tumor compared to normal kidney tissue of 
the same rat (Fig. IV). Data of southern blot analysis using pViml 
could not reveal any abnormality in the structure of the vimentin gene 
(data not shown). 
Μ Α В 
Fig IV; Northern blot analysis of vimentin (blot A) and actin (blot B) 
mRNA levels in the original rat renal cell tumor (lanes Al and 81), in 
a tumor specimen of the tenth passage (lanes A2 and 82) and in normal 
rat kidney tissue (lanes A3 and 83). Poly(A) selected RNA from the 
tumor was size-fractioned by agarose gel electrophoresis and analyzed 
by the Northern blot technique. Molecular probes used were pViml for 
vimentin and pActl for actin. Molecular weight markers included were 
single strand HindiII digested labda DNA molecules. 
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H.T.C.S. Results 
In the Human Tumor Cloning System using the double layer soft agar 
method culture the rat renal tumor cells gave a reproducable Temporal 
Growth Pattern (T.G.P.) during the different passages. The peak 
growth of colonies was obtained after about 16 days and colonies 
showed an increase not only in number, but also in the size (Fig. V). 
A plating efficiency of 0.0155» was noticed when 500,000 cells/disk 
were plated. 
COLONIES | SIZE CATHG0RY 
1 60« 
2 7 2 * 
4 10І.К 
0 2 i, 6 β Ί Ο ' 12 '14 'lis ' 18 20 22 DAYS IN CULTURE 
Fig V; Temporal growth patterns in the double layer soft agar human 
tumor cloning system of four size-categories of tumor colonies of a 
cell suspension of the rat renal cell tumor after three passages. 
DISCUSSION 
The purpose of this study was a multidisciplinary analysis and 
characterization of a rat renal cell tumor model system with special 
emphazis to the question whether or not this tumor model is comparable 
to the human renal cell tumor. This would imply that this tumor could 
eventually be used as a model system in cancer drug studies. Such a 
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model for renal cell tumor should have the following properties: 
1) it must have originated (spontaneously) from rat renal cell tissue; 
2) it must be maintainable in a stable form during long term passages; 
3) the tumor should have histological, biological and biochemical 
characteristics identical or very similar to the human renal cell 
tumor. 
The murine tumor evaluated in this paper, originated in a male Wistar 
Lewis rat and was maintained over several years by subcutaneous 
transplantation as described before (deVere White and Olsson, 1980). 
According to these authors the tumor arose spontaneously, was hormone 
independent and could be readily transplanted. In our hands, in 90% of 
all tumor transplantations a reproducable tumor growth curve could be 
monitored in the recipient animals. 
As far as histological and biochemical characteristics are concerned, 
we can state that this rat renal cell tumor model shows properties 
that closely resemble the human renal cell tumor. The histology as 
deduced from paraffin sections is that of a typical clear cell type 
Grawitz tumor. Electron microscopic examinations of the rat tumor 
revealed the presence of two different cell types. Ultrastructural 
studies also showed that this mixed type of renal cell tumor is 
composed of electron-dense and electron-light tumor cells. The 
electron-dense cells showed a more epitheloid organization with 
occasional formation of glandlike structures. 
Incomplete basal lamina mostly surrounded islets of electron-dense 
cells. The electron-light cells showed a more interspersed 
distribution. All cells show the presence of high amounts of glycogen 
and lipids, a feature which is typical for the human clear cell 
component of renal cell tumor. Whether or not the two different cell 
types seen in the EM in the rat renal cell tumor have their human 
counterparts in the clear cell and granular cell types remains to be 
answered (Bennington and Beckwith, 1975). 
From the intermediate filament studies it appeared that most rat renal 
cell tumor cells co-express cytokeratins and vimentin. The presence of 
cytokeratins, as detected by a broadly cross-reacting rabbit 
antiserum, shows the epithelial nature of the rat tumor. The 
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occurrence of cytokeratin 18 within the tumor, as demonstrated by a 
monoclonal antibody (RGE 53) suggests an adenocarcinomatous 
character. It furthermore supports the assumption that this tumor has 
its origin in (part of) the ductular structures of the kidney. 
Next to cytokeratin type of IFP the tumor cells also contain vimentin. 
Double label experiments have shown that renal cell tumor cells can 
express both cytokeratin and vimentin while others express only 
cytokeratins, thus confirming our earlier studies on human renal 
tumors in which the same properties of intermediate filament 
expression were seen (Herman et al., 1983). 
In general, the vimentin type of IFP preferentially occurs in 
mesenchymal cell types, but has also been demonstrated to be present 
in some epithelial neoplasms, amongst which the Grawitz type of kidney 
tumor. It is therefore that this phenomenon adds further evidence to 
the renal cell carcinoma nature of the tumor studied here. It should 
be kept in mind however, that also the fact that this tumor is 
constantly transplanted may partly be responsable for this vimentin 
expression. Also at the RNA level a three-fold increase of the 
vimentin mRNA in the rat tumor as compared to normal rat kidney tissue 
could be shown. The increase of the vimentin mRNA level is probably 
due to the greater number of cells expressing the vimentin gene, 
however, it cannot be excluded that overexpression is responsable for 
this phenomenon. No structural disorders in the genomic organization 
were seen. Also in human renal cell tumors a drastic increase of the 
vimentin mRNA level has been detected (personal communication). 
By means of two dimensional DNA flow cytometric analysis, the DNA 
content of the vimentin and cytokeratin positive cells could be 
compared and the proliferative fraction of the tumor cells could be 
analyzed separately from (cytokeratin negative) stromal and 
inflammatory cells (Feitz et al., 19 6а). The coexpression of vimentin 
and cytokeratin can be seen in the aneuploid fraction which was found 
in this renal cell tumor, while the diploid fraction proved to be 
cytokeratin negative. These data are comparable to the findings in 
human renal cell tumor (Herman et al., 1983; Feitz et al., 1986a) and 
they give support to the biological comparability of the rat and human 
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renal cell tumor. 
Finally, the tumor was also tested in the Human Tumor Cloning System 
(Hamburger and Salmon, 1977) in order to evaluate its growth capacity 
and behaviour in this in vitro culture system, using a dynamic culture 
evaluation method. Cell suspensions of tumors of different passages 
showed a reproducable Temporal Growth Pattern (Verheijen et al., 
1985). In summary we can conclude that the rat renal cell tumor model 
described here shows a similar histological and biochemical profile as 
compared to human renal cell tumor and is therefore a suitable model 
for studying effects of new or experimental drugs on renal cell tumor, 
provided that the precautions necessary for comparing each animal 
model with the human counterpart are kept. 
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ABSTRACT 
Four human renal cell carcinoma xenografts (RC2, RC-14, RC43, N65), 
maintained in nude mice during several years, were studied in a 
multidisciplinary set up, using (inmuno)histochemical, biochemical and 
ultrastructural techniques. Histological, cellular, nuclear and 
biological characteristics were investigated. All tumors showed 
histologically recognizable features of human renal cell carcinomas, 
although marked differences between the four tumors were seen, both at 
the histological and ultrastructural level. Flowcytometric analysis of 
tumor cell suspensions allowed DNA quantification as well as the 
detection of subpopulations. Immunohistochemical staining procedures 
using tissue specific antibodies against intermediate filament 
proteins revealed two populations of tumor cells. Most tumor cells in 
three of the xenografts coexpressed cytokeratins and vimentins, while 
in RC43 most of the tumor cells expressed only vimentin. Northern blot 
analysis showed a higher expression of vimentin mRNA in all tumors as 
compared to normal kidney tissue. RC43 showed a three-fold higher 
level of vimentin mRNA then the other xenografts. Growth potential in 
the human tumor cloning system was evaluated by temporal growth 
pattern analysis. 
These experiments showed that in the xenografts resemble human primary 
renal cell tumors in different ways, and reflect different 
characteristics that can be present in human renal cell carcinomas. 
INTRODUCTION 
Recent developments in cell biology have led to the identification of 
new tumor cell parameters that allow a more accurate tumor 
characterization. In renal cell carcinoma histological classification 
alone can sofar not provide the clinician with sufficient information 
to predict the course of the disease (1). Additional information has 
become available from biochemical and cell biological techniques such 
as the analysis of cellular DNA by flow cytometry (2, 3, 4 ) . Also the 
immunohistochemical identification of different cellular constituents 
has given further insight in renal cell tumor biology (5, 6, 7, 8). 
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Also differences in gene expression in renal cell carcinomas as 
compared to normal kidney have been investigated (9). 
Since they are used as a model system for the human situation we have 
investigated some of these parameters in four different human renal 
cell tumor xenografts which were continuously transplanted in nude 
mice, in order to establish the biological properties of these tumor 
lines. 
Although they do not completely resemble the human situation, these 
human xenografts are more closely related to it than the 
transplantable experimental animal tumors (10, 11). Human renal cell 
carcinoma xenografts in nude mice retain their histological and 
electron microscopical features (12, 13), and show a chromosomal 
stability (14). Also the grade of nuclear atypia, the predominant cell 
type and abnormalities in cholesterol metabolism remained the same 
(15). While also HLA expression remained consistent (16). The mitotic 
index, however, was reported to be higher than that of the original 
tumor (17). 
For our study, four xenografts (RC2, RC14, RC43 and NC65), originating 
from patients with metastatic disease at the time of diagnosis, were 
established in nude mice. These tumors have been described to have a 
comparable histology to the original tumors (IB). We further evaluated 
the four tumors by immunohistochemical methods, flow cytometry, growth 
potential, and by the Southern (19) and Northern blot technique, to 
evaluate the vimentin gene expression in relation to 
immunohistochemical findings. 
MATERIALS AND METHODS 
Renal cell carcinoma xenografts in nu/nu athymic mice were established 
at the Department of Urology of the Erasmus University, Rotterdam 
(18). 
г «· 4. 1. /no- DPI/, нсдт and NCns) were evaluated in a Four of these tumors (RC2» RC14» HLi*-> ^-ьэ' 
multidisciplinary set-up in order to investigate several biological 
characteristics and potentials of these tumors. 
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Histology; Tissue material of a representative part of the tumor was 
prepared for routine histological examination using hematoxilin and 
eosin (H.E.) staining and a periodic acid schiff (P.A.S.) staining. 
Electron microscopy; tumor material was cut in small pieces and fixed 
in a cacodylate buffered mixture of glutaraldehyde and 
paraformaldehyde. Following postfixation in osmic acid and dehydration 
in graded ethanols they were embedded in Epon. Double contrasted 
ultrathin sections were examined in a Philips EM 300. 
Immunohistochemistry; 5-7 Micron thick frozen sections of the renal 
cell carcinoma xenografts anap frozen in liquid nitrogen were fixed in 
methanol at -20°С for 5 min. and thereafter dipped in aceton at room 
temperature. The indirect immunofluorescence technique was performed 
as described before (7). 
The following antisera were used in this study : 1 ) An affinity 
purified rabbit antiserum to human skin keratins (pKer) for the 
detection of the epithelial nature of a certain tumor. 2) An affinity 
purified rabbit antiserum to bovine lens vimentin (pVim), the 
intermediate filament protein present in mesenchymal cells. 3) A 
monoclonal antibody to cytokeratin 18 (RGE 53) specific for glandular 
epithelial celle (19). 
Flow cytometric analysis; flow cytometric analysis was done on single 
cell suspensions of the xenografts in combination with the two 
parameter labeling technique for the differentiation of subpopulations 
in the tumors as described before (8). Ethanol fixed cell suspensions 
were split into three fractions. One sample was stained with PI and 
used for cell kinetic studies. A second sample was uaed for estimation 
of the DNA-index, with chicken red blood cells as internal standard. 
The third sample was labeled using tissue specific markers 
(cytokeratins and Vimentin) for the detection of tumor cell 
subpopulations. 
Northern blot analysis; Vimentin mRNA level with actin as a standard, 
was detected using pViml and pActl as DNA probes (20). Preparation of 
the DNA probe and its nick translation (21) was carried out as 
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described before (22). Primer extension reactions were according to 
Messing and co-workers (23). The specific activity of the probes used 
in the hybridization studies was 2-5 χ 10Ö cpm/pg. Agarose gel 
electrophoresis and hybridization analysis was performed as described 
before (22). Total cellular RNA was isolated according to the 
procedure described by Auffray and Rougeon (24). Upon poly(A) 
selection by oligo(dT)-cellulose chromatography, the mRNA was 
dissolved in sodium phosphate buffer (10 mM, pH 7.0), containing (505») 
DMSO and (1 M) glyoxal, and heated to 50° С for 1 h. RNA was size 
fractionated by agarose gel electrophoresis (1.0% agarose gel) and 
transferred to Hybond N (Amersham) for hybridization analysis as 
described before (25). 
Human tumor clonogenic cell culture system (HTC^S): For the detection 
of growth potential in .the soft agar double layer cell culture system 
single cell suspensions of the tumors were prepared. Tissue selected 
for soft agar culture was processed according to the detailed 
description published by Salmon (26). A modified two layer soft agar 
culture method as described before (27, 28) was used. The cells were 
cultured immediately after preparation of the single cell suspension 
and cell growth estimation using the Omnicon FAS II automated colony 
counter (Milton Roy Inc., Rochester, New York, USA) as described 
before (29). For dynamic colony growth development evaluation we used 
the "Temporal Growth Pattern" (TGP), giving an estimation of the 
growth over a certain period of time (28). 
RESULTS 
All four xenografts investigated are known to be derived from primary 
metastatic human renal cell carcinomas and were encoded RC2, RC-14, 
RC43 and №¿5 (Table I). 
Histology. RC2 was composed of tumor cells of varying size and 
organized in a somewhat trabecular arrangement. The cytoplasm of the 
tumor cells showed large vacuoles and made an optical empty 
impression. Irregularly shaped nuclei contained macronucleoli with a 
marked variation in shape. Mitoses, mostly abnormal, were often 
-52-
Table I; Results of the multidisciplinary analysis of the four established xenografts 
of renal cell carcinomas in nude mice. 
in vivo vimentin aneupl. DNA growth 
doubling timejhistologyj EM |pVim|pKer|RGE53| mRNA ¡fraction index HTCS 
RC2 11.2 ± 7 d G+C e = m| + + | + |elevated| 9.0% 1.47 | ++ 
RC-,4 3.8 ± 1.2 d С e = m + | + + elevated) 7.5Ä | 1.935 ++ 
I I 
RC43 | 4.0 ± 1.4 d j G-M: e < m ++ - j - elevated) 47.7% j 2.263 j + 
I I I I 
NC65 | 3.6 ± 1 d G+C e = m + | + + [elevated 23.0% | 2.041 ++ 
1 1 1 1 1 1 1 1 1 1 
Meaning of symbols: G= granular cell type, C= clear cell type, e= epithelial 
characteristics, m= mesenchymal characteristics, -= negative, += positive, ++= 
strongly positive, d= days, = is equal to. 
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observed. The tumor was classified as mixed cell type Grawitz tumor of 
moderate differentation (Fig. 1С). 
RCi4 consisted almost completely of cytoplasm rich cells, arranged in 
a tubular and alveolar way. Inbetween the tumor cell nests many 
optical empty spaces or areas filled with erythrocytes were present. 
Mitoses, from many of which atypical, were often observed. The tumor 
cells contained mostly large vacuoles. It was classified as a well 
differentiated pure clear cell type renal cell carcinoma (Fig. IA). 
RC43 showed tumor cells with a spindle-like appearance. A part of the 
tumor cells showed cytoplasmic vacuoles, while most of them revealed a 
fine granular cytoplasm. Nuclei were polygonal, sometimes of a bizar 
shape, containing mostly irregularly shaped macronucleoli. 
Occasionally polynuclear cells were observed. The tumor was classified 
as a poorly differentiated mixed type Grawitz tumor (Fig. ID). 
№ ¿ 5 consisted of tumor cells arranged in tubular or solid structures 
interspersed with extensive areas of stromal tissue and necrosis. The 
tumor showed cytoplasm rich cells with polygonal nuclei containing 
macronucleoli of irregular shape. The cytoplasm contained mostly 
vacuoles but also eosinophilic granular structures were observed. The 
tumor was classified as a moderately differentiated mixed type Grawitz 
tumor (Fig. IB). 
Electron microscopy. All tumors contained cells with well developed 
nuclei and organelles. Junctional complexes as well as glycogen were 
demonstrated in varying amounts (Fig. IIA). The epithelial 
characteristics were distinct in all the cases except for RC43. The 
latter differed in various aspects e.g. more polymorphic nuclei, very 
few junctions and lipid droplets (Fig. IIB). 
Immunohistochemistry. Expression of both the epithelial and 
mesenchymal type of intermediate filament proteins in human renal cell 
carcinoma is well established by rabbit antisera to cytokeratin and 
vimentin, respectively (5, 6, 8). The xenografts RC2, RC14 and NC55 
(Fig. Ill) were also stained by both these antibodies in the clear 
cell as well as the granular cell component. Using the RGE53 
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^* ' χ •·" 
Fig. I: Representative examples of the histology of the human renal 
cell carcinoma xenografts in nude mice of (a) RC14» (b) NC65» (c) R,-2 
and (d) RC43. (
x
 10) 
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moncolonal antibody to cytokeratin 1Θ, coexpression of this 
adenocarcinoma marker and vimentin could be observed in tumor cell 
areas, thus rendering these three xenografts completely 
indistinguishable from original human renal cell carcinomas. In RC43, 
however, almost exclusively a reaction with the vimentin antibody was 
found and no staining with the cytokeratin antibodies. 
Flow cytometric DNA analysis. The flow cytometric DNA analysis 
revealed in all xenografts the presence of two cell populations, one 
with a diploid and one with an aneuploid DNA content. The diploid 
cells most likely represent stromal and inflammatory cells. A two 
parameter flow cytometry technique, using Propidium Jodide for DNA 
quantitation and FITC for the detection of cytokeratins or vimentin 
using the indirect immunofluorescence technique allowed quantification 
of the aneuploid fractions and calculation of the DNA index for each 
tumor separately from the non tumor cells (Table I). 
The flow cytometric data obtained with N0^5 have been illustrated 
elsewhere (8). 
Flow cytometric data obtained for RC43 are shown in Fig. IV. This 
latter tumor was also in these FCM studies found to react almost 
exclusively with the vimentin antiserum and not with the cytokeratin 
antiserum. For further details see legends to Fig. IV. 
Northern and Southern blot analysis. The expression of vimentin was 
also studied by Northern blot analysis (Fig. V), which is indicative 
for the amount and length of vimentin mRNA. Using pViml as a molecular 
probe an increased level of vimentin mRNA was found in all tumors with 
respect to normal kidney tissue. RC43 showed a vimentin mRNA level 
that was three-fold that of the other tumors, which is in good 
agreement with the results of the iiraiunohistochemical analysis using 
vimentin antibodies. By restriction enzyme analysis of the gene 
encoding vimentin, it was shown that no abnormalities in the vimentin 
gene in the tumor tissue could be found (data not shown). 
Human Tumor Cloning System. In double layer soft agar HTC3S all tumors 
showed a temporal growth pattern (TGP). The peak of growth colonies 
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was obtained after about 17 days and colonies showed an increase in 
both size and number (Fig. VI). 
Fig. II; (a) RC·^. 
Electron microscopy of 
three tumor cells with 
indented nuclei. The 
electron-light 
cytoplasm contain 
numerous organelles 
and few glycogen 
particles. The cell 
membranes show 
interdigitations of 
microvilli with 
desmosomal contacts 
(arrows), (x 7700) 
(b) RC43. The tumor 
cells show often 
highly irregular 
nuclei. The scanty 
cytoplasm contains 
polymorfic 
mitochondria and few 
lipid droplets. The 
cells are partly in 
close apposition 
without junctional 
complexes or are 
provided with loosely 
interdigitating 
microvilli of varying 
shape, (x 5500) 
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Fig. Ill: Immunofluorescence micrograph of the NC55 human renal cell 
tumor xenograft in a nude mouse stained with the cytokeratin antiserum 
pKer(a) and with the vimentin antiserum pVim(b) note the co-expression 
of both types of intermediate filament proteins in tumor cells. 
(x 200) 
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Fig. IV; Examples of 
FCM analyses of a 
human renal cell 
tumor xenograft in a 
nude mouse (RC43), 
using the vimentin 
antibody pVim in 
addition to DNA 
staining with PI. 
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(A) One-dimensional FCM DNA pattern of the total cell suspension 
stained with PI. 
(B) A two-dimensional projection of the DNA content and the vimentin 
content of cells present in the tumor cellsuspension. Note that the 
tumor fraction is strongly vimentin positive. 
(C) A three-dimensional projection of the results of the same 
experiments as in (c). 
(D) DNA histogram of the vimentin positive cells present in the cell 
suspension. The cell cycle parameters are indicated in the right upper 
corner. 
A В 
M 
(kb) 1 2 3 ( 2 3 
43 
23 
„ ..·,„;„ 
Fig. V; Northern blot analysis of 
vimentin (blot A) and actin (blot 
B) expression in NC53 (lane A-) and 
B-i ), in RC2 ( lane A2 and B2 ) and in 
RC43 (lane A3 and B3). Poly(A) 
selected RNA from the tumor was 
size-fractioned by agarose gel 
electrophoresis and analyzed for 
the presence of Vimentin mRNA and 
Actin mRNA. Molecular probes used 
were pViml for vimentin and pActl 
for actin. The molecular weight 
markers included were single strand 
Hind III digested lambda DNA 
molecules. 
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Fig. VI; Temporal 
Growth Patterns in the 
double layer soft agar 
human tumor cloning 
system of all four 
xenografts. Of each 
tumor cell suspension 5 
χ 105 cells/dish were 
plated. Obtained growth 
patterns were corrected 
for the tumor fraction 
percentage of each 
specimen as established 
by flowcytometry. 
DISCUSSION 
At the moment no consistingly effective therapy, be it hormonal, 
chemotherapy or immunotherapy for renal cell carcinoma exists (30). 
Investigations attempting to identify and test effective agents with 
in vitro assays have sofar been unsuccessful, in part because of 
technical problems and the refractory nature of renal cell carcinoma 
to currently available chemrtherapeutic agents (31). Additional 
difficulties in clinical evaluation of new treatment protocols are 
caused by the relatively rare occurence of the tumor and the pluriform 
spectrum of its clinical presentation with marked differences in 
prognosis (32). The search for new approaches for the treatment of 
renal cell carcinoma necessitates the use of a reproducable biologic 
testing system in combination »ich a renal tumor model system that has 
predictable behaviour in vitro and in vivo (33). In addition it is 
necessary that the characteristics of the model show a resemblance as 
close as possible to the human tjmor if the treatment results in the 
model have to be transferred to tne in vivo situation in man. 
The human tumor model systems in nude mice are estimated of a higher 
value than the spontaneously evi.ived murine tumors as for instance 
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described by deVere White and Olsson (34, 35). 
As mentioned before, the xenografts investigated sofar have been shown 
to retain histological (18), ultrastructural (17) and cytogenetical 
(14) features of the original renal cell tumors. For the evaluation of 
the four human xenografts, RC2, RC14, RCtf and NC65 described here, 
their original human renal tumors were not available for comparison. 
Histologically, however, they were recognized as typical renal cell 
carcinomas with different characteristics, varying from moderately 
differentiated (RC2, NC^s) to poorly differentiated (RC43) tumors 
consisting of both granular and clear cells. RC14 consisted of a well 
differentiated pure clear cell type tumor. 
At an ultrastructural level all these tumors revealed epithelial 
properties as described by Kurth et al. (17). RC43 differs from the 
other tumors in the fusi formic aspect of most cells with their 
polymorfic nuclei and mitochondria, while it is also noteworthy that 
the amount of desmosomal contacts is very low when compared to the 
other tumors. 
Recent studies (5, 6, 8) have described the intermediate filament 
protein pattern of human renal cell carcinoma. These led to the 
conclusion that renal cell carcinomas consist of cell populations 
expressing different intermediate filament patterns, i.e. cells 
containing only cytokeratins or only vimentin, but also cells 
co-expressing cytokeratins and vimentin. It was anticipated that these 
different biological characteristics may give rise to differences in 
metastatic behaviour of the subpopulations or a difference in 
chemosensitivity. 
Immunohistochemical studies and DNA flow cytometric analyses of the 
xenografts confirmed these findings as in all four cases an abnormal 
DNA atemline expressing cytokeratin and vimentin expression (albeit in 
different amounts) could be detected. Evaluation of vimentin 
expression by RNA analysis showed an increase of transcription in all 
tumors. RC43 showed an even three-fold higher vimentin expression than 
the other three tumors. In the HTC3S all tumors could be cultured, 
possibly due to the fact that they already were selected for their in 
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vitro growth potential by their succesful growth as xenografts in nude 
mice (36). 
From this study, it can be concluded that the four xenografts contain 
a variety of biological properties that also occur specifically in 
human renal cell carcinoma. It is clear that the individual xenografts 
are different and that none of these tumors unites all 
characteristics. Therefore one should realize that succesful results 
in chemosensitivity tests with one of these tumor models can not 
immediately be transferred to the human situation of renal cell 
carcinoma in general. 
Characterization of each of these xenografts was also performed to see 
if these tumor models represent the different subpopulations of renal 
cell carcinoma tumor cells. Future studies, comparing different 
biological parameters of the tumors, such as oncogene expression and 
in vitro chemosensitivity, will have to show whether these tumors 
represent subtypes of renal cell carcinoma. If a differentiated 
response to treatment protocols is observed, these xenografts may be 
useful tumor models for the study of new experimental 
chemotherapeutics. 
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ABSTRACT 
In a recent paper, we described the expression pattern of 
proto-oncogenes in primary human renal cell carcinomas (12). To test 
the possibility of using xenografts as a useful alternative for such 
studies, we have analyzed xenografts of a number of human renal cell 
carcinomas in nu/nu mice. Xenografts included RC2, RC14, RC21, RC43 
and NC65. Northern blot analysis indicated that с-газ was expressed in 
all these xenografts. The identity of the ras transcripts in the 
individual xenografts was further specified as c-Ha-ras, c-Ki-ras or 
N-ras. Expression of c-myc and the p53 gene was also found in a number 
of these tumors. Only RC21 failed to express the c-myc or the p53 
gene. In all xenografts, a 3.0 kb c-fes/fps mRNA was present. In RC2, 
RC1A, RC21 and RC43, low levels of the A.8 kb abl transcript were 
detectable. Transcripts of myb and sis could not be detected in any of 
the xenografts. The results indicated that the expression pattern of a 
variety of proto-oncogenes in xenografts of human renal cell 
carcinomas was similar to that in the primary tumors. 
INTRODUCTION 
Molecular oncology has led to the discovery of genes whose malignant 
potential becomes apparent upon retroviral transduction of these 
genes. Because of this characteristic, the genes are also thought to 
be implicated in the onset and development of naturally ocurnng 
tumors. Collectively, they are called proto-oncogenes. Up to this 
moment, more than fourty proto-oncogenes are characterized (3, 4). 
Recently, classification of proto-oncogenes in a nuclear and 
cytoplasmic group was proposed on the basis of the site of action of 
their gene products (27). The nuclear group is the smallest one and 
include c-myc, c-myb and the p53 gene. An important characteristic of 
these genes is their immortalizing capacity. In general, the nuclear 
group of proto-oncogenes is weak in inducing anchorage Independent 
growth of fibroblasts in tissue culture (27). There are indications 
that these genes are involved in regulation of gene expression and 
that disturbances in their own expression patterns (in place and/or in 
time) is a major factor in tumorigenesis (2, 15). The gene products of 
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с-myс and c-myb are structurally homologous (6, 20). p53 is a 
phosphoprotein that is overexpressed in some 'transformed cells (11, 
29). The cytoplasmic group of proto-oncogenes is larger and its 
members are thought to be a major factor in processes involved in 
malignant transformation. Proto-oncogenes of this group include for 
instance the ras-gene family, c-fea and c-abl. It has been suggested 
that in general their malignant activation is the result of mutations 
(15). The gene products of c-abl and c-fes are tyrosine-specific 
protein kinases (ID, 22, 24) and the ras gene product resembles the 
G-protein and probably acts as a signal transducer (4, 27). A 
proto-oncogene that does not belong to either of the groups described 
above, is the sis proto-oncogene. Its translation product is highly 
similar to the B-chain of the platelet-derived growth factor (PDGF) 
(17). 
In a recent paper (12), we have described proto-oncogene expression 
patterns in primary human renal cell carcinomas. We found that c-ras 
and c-myc were clearly detectable in most of the tumors. Furthermore, 
expression of c-fes was observed in a small percentage of these 
tumors. Since RNA isolated from primary human renal cell carcinomas 
was often of low quality probably due to necrosis in the tumor, we 
wanted to test xenograft tumor lines of renal cell carcinomas in nu/nu 
mice as a suitable alternative. The nu/nu mouse, described by Flanagan 
(1966) (7) and later found to be thymus deficient and lacking T-cell 
mediated immune response by Pantelouns (196Θ) (1Θ), was chosen as an 
animal host for this type of transplantation experiments, because of 
its usefulness for a wide range of human tumors (Θ). We already 
described that, histologically and ultrastructurally, xenografts of 
human renal cell carcinomas in nu/nu mice resemble primary renal 
tumors (13). 
In the present study, we have studied expression of c-Ha-ras, 
c-Ki-ras, N-ras, c-myc, c-myb, c-abl, c-fes, c-sia and the p53 gene by 
Northern blot analysis in xenografts of five different human renal 
cell carcinomas and an established kidney cell line of a monkey 
(Vero). 
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MATERIALS AND METHODS 
Tumor materials 
Xenografts of human renal cell carcinomas in nu/nu mice were obtained 
from the Department of Urology, Dijkzigt Hospital, Rotterdam. All 
xenografts were derived from primary tumors of patients with apparent 
metastases at the time of diagnosis. Xenografts showed no 
dedifferentiation compared to the original tumors (14). Upon removal, 
tumor material was immediately frozen in liquid nitrogen. The 
established kidney cell line (Vero), derived from an African green 
monkey, was also included in this study. 
RNA isolation and Northern blot analysis 
Total cellular RNA was isolated according to the procedure described 
by Auffray and Rougeon (1). Upon poly(A) selection by 
oligo(dT)-cellulose chromatography, RNA was dissolved in sodium 
phosphate buffer (10 mM, pH 7.0), which contained DMSO (50%) and 
glyoxal (1 M), and heated at 50 °C for 1 hr. RNA was size fractionated 
by agarose gel electrophoresis (1.0% agarose gel) and transferred to 
nitrocellulose or Hybond-N membrane as described before (22). 
Preparation of molecular probes 
The characteristics of the molecular probes used in this study are 
summarized in Table I. The probes were prepared as described before 
(14). Radioactive labeling of the probes was performed according to 
Van den Ouweland et al. (17). 
Hybridization and dehybridization 
Hybridization was performed under conditions as described by Church 
and Gilbert (5) and dehybridization according to the procedures as 
recommended by Amersham. 
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Table I: DNA fragments used as molecular probes. 
1 
I Proto-oncogene 
| N-ras 
| 
1 
1 v-Ki-ras 
1 
1 
c-Ha-ras 
c-myc 
c-myb 
p53 gene 
j v - a b l 
j c - f e s 
1 c - s i s 
1 
Fragment used 
Sal l/EcoRI 
EcoRI/EcoRI 
Smal/Smal 
S a d / S a d 
ВапШ/ХЬаІ 
P s t l / P s t I 
P s t l / P s t I 
EcoRI/EcoRI 
BanHI/BamHI 
as probe 
0.65 kbp 
1.15 kbp 
0.65 kbp 
1.20 kbp 
U.8U kbp 
0.55 kbp 
0.70 kbp 
0.95 kb 
1 . 0 kbp 
I 
Reference 
(9) | 
(25) 
(25) 
(6) | 
(19) | 
(11) | 
(24) | 
(22) | 
(17) | 
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RESULTS 
Expression patterns of proto-oncogenes from the ras gene family are 
well documented. The human с-На-газ mRNA is 1.4 kb (25, 28), the human 
N-гвз-specific transcript is 2.2 kb (9) and transcription of the human 
c-Ki-ras gene results in a 4.6 kb mRNA (25). A complicating factor in 
the interpretation of results concerning ras expression is the fact 
that the ras genes are strongly homologous, therefore 
crosshybridization is often observed in Northern blot analysis. This 
is illustrated in Fig. 1 (lanes A to D ) , in which typical газ 
hybridization patterns are shown, using an N-ras (lane Α-B), c-Ki-ras 
(lane C) and a c-Ha-ras (lane D) probe. In lane A (Fig. 1), it is 
clearly shown that the N-ras probe in addition the N-ras-specifie 
mRNAs (doublet at 2.2 kb) also detects the c-Ki-ras (4.6 kb) and the 
c-Ha-ras transcript (1.4 kb). In the interpretation of the results 
described in this report, however, only specific transcripts are 
considered, namely 1.4 kb for c-Ha-ras, 2.2. kb for N-ras and 4.6 kb 
for c-Ki-ras. It is evident that because of crosshybridization ras 
expression cannot be studied unambiguously by a dot blot assay, but 
requires Northern blot analysis. 
The results of the ras gene expression studies are summarized in table 
II. All tumors except RC21 showed detectable levels of N-ras 
transcripts. It appeared that both RC2 and RC43 contained the highest 
level of c-Ki-ras mRNA. It should be noticed that in these two tumor 
lines also a second mRNA at approximately 5.3 kb was visualized using 
the v-Ki-ras probe. c-Ha-ras expression was the highest in RC21 and 
was not found in RC2 and NC65. From these data it appeared that in 
each of the tumors at least one of the ras genes was expressed. 
Expression of c-myc, c-myb and P53 
The cellular localization of proto-oncogene producta is indicative for 
their mode of action and for the way they play a role in 
carcinogenesis. The c-myc, c-myb and ρ53 gene products are all 
localized in the cell nucleus. Expression of these oncogenes was aleo 
studied by a Northern blot analysis and the results are summarized in 
table II. In none of the xenografts detectable levels of c-myb were 
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Fig. 1; Northern blot analysis of xenografts of human renal cell 
carcinomas. Poly-A selected RNA from RC2 (lane E, F and H), RC14 (lane 
В and D) RC43 (lane С and G) and Vero (lane A) was size fractioned by 
agarose gel electrophoresis and analyzed by Northern blot technique. 
Molecular probes used were N-ras (lane A and B), v-Ki-ras (lane C), 
c-Ha-ras (lane D), c-myc (lane E), p53 (lane F), c-fes (lane G) and 
v-abl (lane H). 
Molecular weight markers included are single strand Hindlll digested 
lambda DNA molecules. 
A B C D E F G H 
2-3 
20 
• 
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Table II; Summary of proto-oncogene expression in xenografts of human 
renal cell carcinomas and the Vero cell line. 
probe 
N-ras 
c-Ki-ras 
c-Ha-ras 
c-myc 
c-myb 
p53 
c-fes 
v-abl 
1 
ι 1 
v-sis 
mRNA 
2.2 kb 
4.6 kb 
1.4 kb 
2.3 kb 
5.0 kb 
3.0 kb 
3.0 kb 
6.6 kb 
4. θ kb 
2.9 kb 
0.Θ kb 
3.5 kb 
RC2 
+ 
++ 
Ü 
U 
++ 
++ 
0 
+ 
0 
0 
0 
RC14 
+ 
+ 
+ 
++ 
0 
0 
+ 
0 
+ 
+ 
0 
0 
RC21 
0 
+ 
++ 
0 
0 
0 
+ 
0 
+ 
0 
0 
0 
RC43 
+ 
++ 
+ 
+++ 
0 
+ 
++ 
0 
+ 
0 
0 
0 
NC65 
+ 
+ 
0 
++ 
0 
0 
+ 
0 
0 
0 
0 
0 
1 
Vero j 
- 1 
NT 
NT j 
NT 
ΰ
 1 
- 1 
0 
- 1 
+++ 
- 1 
NT | 
NT | 
1 
Symbols: 0: no expression detected; + to -t-t-t-: detectable to high 
levels of expression; NT: not tested. 
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present, which is in agreement with the fact that c-myb expression is 
predominantly confined to hematopoetic malignancies (19). High levels 
of c-myc expression were found in all xenografts, except in RC21. The 
possibility that in RC21 another member of the myc gene family (N-myc 
or L-myc) was expressed was not tested and can therefore not be 
excluded. 
The human p53 specific transcript was found at elevated levels in RC2 
and RC43. These data indicate that in most of the xenografts tested, 
detectable levels of mRNA of a nuclear proto-oncogene were present. 
Expression of c-abl and c-fes/fps 
The c-abl and c-fes proto-oncogenes both contain a domain that encodes 
a tyrosine-specific protein kinase (21). The gene products of 
these two genes are localized in the cytoplasm and at least a fraction 
of them seems associated with membranes. Unlike газ and myc/p53, 
elevated expression of these genes is not common in human malignancies 
(25). Detectable levels of fes transcripts are sometimes found in 
haematopoetic malignancies (25), lung tumors (25), breast carcinomas 
and renal cell carcinomas (12, 25). Expression of c-abl in primary 
tumors is only reported in the case of chronic myelogenous leukemia 
(25). Northern blot analysis of RNA of the xenografts revealed that 4 
out of 5 tumors exhibited abl expression. They included RC2, RC43, RC4 
and RC21. The Vero kidney cell line also expressed the abl 
proto-oncogene. In contrast to the xenografts, a number of different 
abl transcripts were found in the cell line. As far as the expression 
of the fes/fps proto-oncogene was concerned, in all xenografts a 3.0 
kb fes/fps specific mRNA was found (Fig. 2). Some fluctuation in the 
levels of the transcripts was observed. No fes/fps transcript could be 
detected in the Vero kidney cell line. The fact that c-fes/fps 
expression was found in xenografts of human renal cell carcinomas is 
in agreement with previous studies on primary renal tumors (12, 25). 
Expression of c-sis 
The c-sis proto-oncogene contains sequences that could encode a 
protein similar to the B-chain of platelet-denved-growth factor 
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(PDGF). A concensus is emerging that in fact the c-sis locus encodes 
the B-chain of PDGF. It was of interest to see whether in renal cell 
carcinomas autocrine growth stimulation as a consequence of c-sis 
activity was involved. Northern blot analysis revealed no c-sis 
transcripts and, therefore autocrine growth stimulation as a 
consequence of c-sis activation can be ruled out. 
A 
I І І І І І І І І І І І І І І — І І І І В а ^ Н И Й Я — 
Fig. 2; Comparative Northern blot analysis of c-fes mRNA in xenografts 
RC2 (lane 2), RC8 (lane 3), RC14 (lane 5), RC21 (lane 6), RC43 (lane 
4) and NC65 (lane 1). The c-fes EcoR1EcoR1 0.95 kb DNA fragment was 
used as a molecular probe. Molecular weight markers included are 
single strand Hindlll digested lambda DNA molecules. 
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DISCUSSION 
Proto-oncogene expression patterns in xenografts of human renal cell 
carcinomas were studied to determine whether xenografts could be used 
as an alternative for primary renal cell carcinomas. A major problem 
in studying mRNA from primary human renal cell carcinomas is 
degradation of mRNA. In contrast to primary tumors high amounts of 
intact mRNA could be isolated routinely from xenografts of human renal 
cell carcinomas. This was probably due to the fact that the time 
period elapsing between excision of the primary tumor and its freezing 
m liquid nitrogen was much longer in the clincal setting than under 
condition of a laboratory experiment. It is well established that 
tumor devitalization already starts when the renal vascular pedicle in 
radical nephrectomy is clamped. The better presentation of tumor 
tissue in xenografts was confirmed by microscopical examination of the 
xenografts revealing homogenous tumor structures and almost no 
necrosis. 
Our results indicated that as far as proto-oncogene expression 
patterns are concerned, xenografts of human renal cell carcinomas 
provide a good alternative for primary tumors. Expression of all three 
members of the ras gene family was found in the xenografts. This is in 
accordance with earlier observations in primary renal tumors in our 
laboratory (Schalken, unpublished observation) and in agreement with 
results from other groups (25). 
Similarly, expression of c-myc in xenografts is also in good agreement 
with studies on primary tumors. The fact that in one of the 
xenograft tumor lines no c-myc transcripts could be found does not 
necessarily mean that this tumor does not contain a transcript that is 
related to c-myc. In recent studies (16), the discovery of N-myc and 
L-myc genes were described and they are related to the c-myc gene. 
However, limited nucleotide sequence homology could explain the 
failure to detect transcripts of them with a c-myc probe, especially 
under the hybridization condition of high stringency that were used. 
Expression of the c-fes/fps proto-oncogene in renal cell tumors is a 
matter of interest. In contrast to primary human renal cell carcinomas 
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Fig. 3; Schematic representation of the human genomic region 
containing the fur gene and the fes/fps proto-oncogene. The putative 
promotor region is situated between the BamHI and PstI site. E= EcoRI; 
B= BamHI; P= PstI. The restriction endonucleases placed between 
brackets indicate that not all the cleavage sites for this enzyme are 
depicted. 
.fur 
•¿ΝΕ­
Ε 
(P) 
ι 
. fes/fps 
E 
J 
(B) 
45kbfur mRNA 30 kb fes/fps mRNA 
- 8 1 -
in which с-fes/fps expression was found in only IOS of the cases, the 
xenografts exhibited in all cases tested a clearly elevated level of 
fes/fps expression. At the moment it is not clear how to explain this 
observation. It is well established that in normal cells expression of 
c-fes/fps is restricted to cells of hemopoietic origin and mainly to 
those of the myeloid lineage (2Θ). The possibility that many myeloid 
cells were present in the xenografts and that the observed fes/fps 
expression was due to such cells in the tumor specimens could be ruled 
out on the basis of histopathological analysis. The fact that all 
xenografts exhibited fes/fps expression suggests that 
xenograft-specific factors are involved and may be selected for, 
during in vivo propagation of the tumor cells. In situ hybridization 
or immunofluorescence analysis could shed light upon this matter by 
identifying in xenografts as well as in primary tumors the cell types 
that express the proto-oncogene. 
The high levels of fes/fps expression in xenografts of renal cell 
carcinomas is also remarkable. In specimens of normal kidney, the 
fes/fps DNA region seems transcriptionally silent. The genetic region 
immediately upstream of the proto-oncogene, however, is 
transcriptionally active in tissue specimens of normal kidney (22). 
This region, which we have designated fur (for fes/fps upstream 
region) contains a gene, which is located very closely (less than 1 
kbp) to the proto-oncogene (22). For a schematic representation of 
this genetic region in the human genome, see Fig. 3. The fur gene, 
which seems to encode a membrane associated protein with a recognition 
function, has a relatively strong promoter (23). The promoter of the 
proto-oncogene remains to be identified. It is tempting to speculate 
that in renal cell carcinomas the promoter region of the fur gene is 
involved in expression of the proto-oncogene. The fact that xenografts 
of human renal cell carcinomas resemble primary renal cell carcinomas 
and that mRNA of high quality can be isolated from them enables 
characterization of the fes/fps transcription unit in these tumor 
cells by cDNA analysis and SI nuclease protection experiments. By this 
approach, the hypothesis mentioned above can be tested now. 
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CHAPTER V 
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ABSTRACT 
Nine primary human renal cell tumors (RCT), one lymphnode metastasis, 
4 human xenografts of a RCT in nude mice and a rat RCT line were 
analysed by flow cytometry (FCM) using propidium iodide for DNA 
analysis and antibodies to cytokeratin and vimentin in the indirect 
immunofluorescence technique for labelling of specific tumor cell 
populations. By means of Z-dimensional FCM analysis, vimentin- and 
cytokeratin-positive (tumor) cells were compared and their DNA content 
and proliferative fraction could be analysed separately from those of 
cytokeratin-negative stromal and inflammatory cells. In primary human 
RCT, 2 subpopulations of cells were detected and analysed separately. 
Small numbers of tumor cells with an abnormal DNA stemline were also 
detected. In addition, co-expression of intermediate filament proteins 
of both the cytokeratin and the vimentin types was detected in the 
aneuploid cell population. Comparison of 2 model systems of RCT with 
primary human RCT revealed a similar pattern of tumor cell 
subfractions within these tumors. The 2-parameter FCM analysis permits 
the detection of subpopulations in complex cell suspensions and the 
quantification of these fractions, as well as analysis of their 
cellular DNA content. 
INTRODUCTION 
In a recent report (Feitz et al., 19B5) we have evaluated the 
usefulness of DNA flow cytometry (FCM) in combination with staining of 
the cytoplasmic intermediate filament proteins in bladder carcinomas. 
These tissue-specific proteins can be detected immunocytochemically by 
means of monoclonal and polyclonal antibodies and can be used in the 
FCM analysis of complex human tumors (Ramaekers et al., 19 4а, b, 
1986). In particular, antibodies to cytokeratins, the intermediate 
filament proteins specific for epithelial cells, enable carcinoma 
cella to be analyzed separately from the non-epithelial stromal and 
inflammatory cell componente that are present in most tumors. 
Investigation of human primary renal cell tumors (RCT) showed that 
these neoplasms contain several tumor cell populations, each with a 
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different intermediate filament staining pattern. Cytokeratin was 
found in many tumors, but nearly all tumors co-expressed the 
mesenchymal type of intermediate filament protein vimentin. However, 
primary RCT and lymphnode metastases of RCT also contained either 
cytokeratin or vimentin only (Herman et al., 19B3a). Therefore, we 
suspect that biological differences in the subfractions of RCT may 
give rise to differences in behaviour of tumor metastases, and 
undoubtedly have consequences of chemotherapy. 
The development of model systems for further cell biological and 
experimental investigations of RCT has led to the establishment of 4 
human renal cell xenografts in nude mice (Kurth et al., 1984) and of a 
tumor line from a rat RCT in Wistar Lewis rats (deVere White et al., 
19B0). In this study, we present findings on the 2-parameter FCM 
analysis of cellular DNA and intermediate filament content of these 
RCT models in comparison with primary human kidney tumors. We have 
tried to answer the following questions: 
(1) Does application of this 2-parameter analysis to RCT allow 
separation of the tumor cells from inflammatory and stromal cells, 
making it possible to estimate ploidy and proliferative fractions more 
accurately, as in the case of bladder carcinoma (Feitz et al., 19Θ5)? 
(2) Do aneuploid (tumor) cells contain both cytokeratin and vimentin? 
(3) How can RCT animal model systems be compared with primary human 
RCT? 
MATERIAL AND METHODS 
Nine primary renal cell tumors (RCT) and one RCT metastasis (number 1 
to 10 in Table I), 4 human RCT xenografts in nude mice (designated 
RC2, RC14, RC43, NC65) and a rat RCT line (designated rRCT) 
continuously retransplanted in Wistar Lewis rats (deVere White et al., 
1980) were used in this study (Table I). Representative parts of tumor 
tissue were chosen which included all macroscopically identifiable 
histological patterns of the tumor. Necrotic and hemorrhagic areas 
were excluded. The material was divided into 3 parts: one part was 
fixed in formalin and embedded in paraffin for routine histology, 
another was snap-frozen in liquid nitrogen for iiranunohistochemical 
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Table I; DNA index of RCT obtained after the one- (DNA iidex) and 
2-parameter FCM analysis (DNA index pKer and DNA pVim). In the cases 
in which an aneuploid tumor cell fraction was present, the DNA index 
of this latter fraction is given only 
NUMBER 
1 
I 2 
I 3 
4 
5 
6 
I 7* 
I 
9 
10 
RC2 
RC14 
RC43 
NC65 
rRCT 
I 
DNA 
index 
0.97 
0.802 
1.40 
0.98 
0.94 
0.96 
0.95 
1.19 
0.93 
1.66 
1.40 
1.87 
2.24 
0.97 
0.98 
DNA index 
(pKer) 
0.97 
0.802 
1.36 
1.30І 
0.94 
1.60 1 
1.54І 
1.30 
0.96 
1.66 
1.39 
1.84 
2.29 
1.881 
1.881 
DNA index 
(pVim) 
0.97 
L O S 2 
1.35 
1.Э5І 
0.94 
І.бО
1 
_ 3 
1.17 
0.97 
1.66 
1.40 
1.77 
2.35 
1.92 1 
1.87 1 
1 In these cases labelling with either cytokeratin or vimentin 
antibodies resulted in the detection of an aneuploid peak not seen 
without labelling. 
2 Hypoploid tumor cell fraction present in the suspension (cf. Fig. 
2c, d). 
3 Some aneuploid cells. 
Human RCT (1 to 10, 7* is a lymphnode metastasis from 6), RCT 
xenografts (RC2, RC14, RC43, NC65) and a rat RCT (rRCT). 
staining reactions, and a third was used for preparation of a single 
cell suspension for FCM. 
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Routine histological classification was done from 
hematoxylin-eosin-stained paraffin sections (Bennington and Beckwith, 
1975). 
Cell suspensions were prepared from the fresh tissues as described 
before (Herman et al., 1983b; Feitz et al., 1985). From solid tumor 
material single cell suspensions were prepared by mechanical and 
enzymatic disaggregation using a mixture of collagenase Type II (1176 
U/ml, Worthington, Freehold, NY) and DNase I (200 U/ml, Sigma, St. 
Louis, MO) at 37 "C for 2 hr. After 3 subsequent filtration steps 
(300-jj metal sieve, 25-gauge needle and 50-μ pore size nylon filter) a 
single cell suspension was obtained and the cells were fixed in 70% 
ethanol (-20 °C) and stored at -20 °C to -40 "C until further 
processing. 
Immunohistochemical staining procedures and antibodies 
Frozen sections of normal kidney tissue, primary RCT and a metastasis, 
as well as 4 xenografts of RCT and a rat RCT, were incubated with 
intermediate filament antibodies by the indirect immunofluorescence 
technique (Ramaekers et al., 1983b). Antibodies used in this study 
were: (1) An affinity purified polyclonal rabbit antiserum to human 
skin keratins (pKer) which reacts with virtually all epithelial 
tissues, but not with non-epithelial tissues. The antiserum was 
diluted 1:5 in PBS for staining of cells in suspension and 1:25 for 
staining of frozen sections. (2) An antiserum to calf lens vimentin 
(pVim), raised in a rabbit. Preparation and specificity of this 
antiserum have been described (Ramaekers et al., 19B3b). 
Ethanol fixed cell suspensions from RCT were split into 4 fractions. 
One sample was stained with propidium iodide (PI) as described below 
and used for cell kinetic studies. A second sample was used for 
calculation of the DNA index, using chicken red blood cells (CRBC) as 
internal standard (Hamilton et al., 1980; Tannenbaum et al., 1978). 
The other 2 samples were stained separately with the antibodies pKer 
and pVim (Feitz et al., 1985; Oud et al., 1985; Ramaekers et al., 
19B4a, b, 1986). In brief, cells were incubated for 30 min with the 
antibody directed against the specific intermediate filament proteins, 
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washed several times, and incubated with an appropriate 
FITC-conjugated second antibody for 30 m m . Thereafter, DNA staining 
was performed using propidium iodide (PI) on RNase treated cells. 
FCM analysis 
Cell analyses were performed using a Cytofluorograph 50H (Ortho 
Instruments, Westwood, MA) as described before (Feitz et al., 19B5). 
All data were stored in correlated (list) mode on a PDP 11/34 computer 
(Digital, Marlboro, MA) for subsequent data analysis. The normal human 
Gì DNA-index in our laboratory is 2.65 to 2.75 times the fluorescence 
intensity of CRBC (Hiddeman et al., 1984). Cell cycle analysis was 
done as described by Baisch et al. (1975). As a control, cells 
incubated only with an FITC-conjugated second antibody were analysed 
and in this control all cells were negative. 
RESULTS 
Imniunohistochemistry 
Frozen sections of normal kidney, primary RCT and a metastasis, human 
xenografts of RCT in nude mice and a rat RCT were incubated with the 
antibodies pKer and pVim (Fig. 1). In normal kidney tissue, epithelial 
structures such as collecting ducts and parietal glomerular epithelial 
cells are stained with the cytokeratin antibody. Staining with the 
vimentin antibody is found only in endothelial and peritubular cells, 
in vascular walls and glomerular cells (Fig. la, b). Primary human RCT 
and xenografts of these tumors as well as a rat RCT were found to 
react with both the cytokeratin and the vimentin antibodies (Fig. 
1c-h). In double labelling studies it was seen that vimentin positive 
cells were also positive for cytokeratin (see also Herman et al., 
1983a). 
Labelling of RCT in single cell suspensions and FCM analysis 
Ethanol fixed tumor cells in a single cell suspension were incubated 
with the antibodies pKer and pVim and thereafter with the 
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Immunofluorescence micrographs of normal kidney (a, b), a 
primary human renal cell tumor (c, d), a xenograft of a human renal 
cell tumor in a nude mouse (NC65) (e, f ), and a rat renal cell tumor 
in Wistar Lewis rats (rRCT) (g, h), stained with the cytokeratin 
antiserum pKer (a, c, e, g) or with the vimentin antiserum pVim (b, d, 
f, h). Note the co-expression of both types of intermediate filament 
proteins in tumor cells, a-h, x150. 
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Fig. 2; Example of a 2-parameter FCM analysis of a primary human RCT 
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Fig. 3: Example of a 2-parameter FCM analysis of a human RCT xenograft 
in a nude mouse (NC65) using the cytokeratin antibody pKer and the 
vimentin antibody pVim in addition to DNA staining with PI. (a) 
One-dimensional FCM DNA pattern of the cell suspension stained only 
with PI. (b) A 2-dimensional projection of the DNA-content (as PI 
fluorescence) and the cytokeratin content (as FITC fluorescence) from 
the same cell suspension as shown in (a), (c) A 2-dimensional 
projection of the DNA content and the vimentin content of the same 
tumor. Note that the tumor fraction is cytokeratin- and 
vimentin-positive. (d) DNA histogram of the cytokeratin-positive cells 
present in the cell suspension. The cell cycle parameters are 
indicated in the upper right corner. 
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Fig. 4: Comparison of the 2-parameter FCM analysis of a primary human 
renal cell tumor (no. 4) (a, b) with 2 tumor model systems, one 
xenograft of a human RCT in a nude mouse (NC65) (c, d) and a rat RCT 
(rRCT) (e, f). (a, b) Two-dimensional projections of the DNA content 
and the cytokeratin-positive (a) and vimentin-positive (b) cell 
fractions of a primary human renal cell tumor, (c, d) Projections of 
DNA content and cytokeratin (c) and vimentin (d) content of a 
xenograft of the human renal cell tumor, and (e, f) a rat renal cell 
tumor (cytokeratin in e and vimentin in f). Note that in all cases the 
tumor fraction is cytokeratin- and vimentin-positive next to 
vimentin-positive stromal cells (A= aneuploid, D= diploid DNA index). 
FITC-conjugated second antibody and PI. In the 9 primary human RCT and 
the lymphnode metastasis, analysed in this way, the vimentin-positive 
cell population contains stromal cells and inflammatory cells (Fig. 
2d) next to the tumor cells, which become clearly visible as an 
aneuploid peak in 7/10 cases (see Table I and Fig. 2b). In these cases 
nearly all tumor cells are also cytokeratin-positive (Fig. 2a, c). The 
cytokeratin-negative cell population is represented by the stromal and 
inflammatory cells of mesenchymal origin which are vimentin-positive. 
Table I summarizes the FCM data obtained for these human RCT before 
and after immunolabelling. This inriunolabelling procedure made it 
possible to detect an abnormal DNA stemline in RCT in 7/10 instead of 
4/10 samples. 
An example of analysis of a tumor cell suspension from a RCT xenograft 
in nude mice is shown in Figure 3. Figure 3a shows the normal DNA 
histogram before labelling with intermediate filament antibodies. 
After labelling with the cytokeratin antibodies, epithelial (tumor) 
cells can be identified and their DNA content and cell cycle 
parameters analysed (Fig. 3b, d). As expected from our 
immunohistochemical findings, tumor cells with an abnormal DNA 
stemline are also found in the vimentin-positive fraction (Fig. 3c). 
These can also be analysed for their DNA content and proliferative 
fraction by placing a window around the vimentin-positive cells. Both 
the cytokeratin and vimentin-positive cell fractions show a similar or 
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identical DNA index, indicating co-expression of both intermediate 
filament proteins in a certain number of the tumor cells. Similar data 
have been obtained for the rat RCT model system. Fig. 4 compares 
2-parameter DNA analysis of a primary human RCT (Fig. 4a, b) with that 
of a human RCT xenograft in a nude mouse (Fig. 4c, d) and that of the 
rat RCT (Fig. 4e, f). All 4 cases of human RCT xenografts in nude mice 
contained an abnormal DNA stemline. Tumor cells expressing 
cytokeratins were found in all 4 tumors while a positive staining 
reaction was also found with the vimentin antibodies in the tumor cell 
population (Fig. 4d), although with varying intensity. The DNA content 
of tumor cells in the xenografts, however, is higher than that of the 
primary human RCT (see Table I and compare Fig. 4a, b with Fig. 4c, 
d). The rat RCT, analysed with the 2-parameter FCM analysis, also 
contained an abnormal DNA stemline with a DNA index of 1.66. The tumor 
fraction contained aneuploid cells expressing both cytokeratin (Fig. 
4e) and vimentin (Fig. 4f). 
DISCUSSION 
Flow cytometric analysis of renal cell tumors offers a new diagnostic 
tool for the clinician and has additional prognostic value (Baisch et 
al., 1962; Herman et al., 1964). Tumors can be further subclassified 
on the basis of this technique and selection of patients at risk is 
made possible by detection of biologically important cell fractions 
(Ljungberg et al., 1965; Lovett et al., 1984; Otto et al., 1984; 
Schwabe et al., 1983; Verheyen et al., 1985). The use of tissue 
specific markers, such as cytokeratins, in combination with DNA 
analysis in flow cytometry permits better analysis of tumor fractions 
within cell suspensions and may provide further information about 
subfractions in complex tumors (Feitz et al., 1985). When polyclonal 
and monoclonal antibodies to cytokeratin and vimentin are used, cell 
subpopulations can be aeparately analysed by the indirect 
immunofluorescence technique. These antibodies are already widely used 
as tissue specific markers in inriunohistopathology and cytopathology 
(Ramaekers et al., 1983b). The use of these tissue specific markers in 
flow cytometric analysis of complex tumors has been described for some 
tumor types (Feitz et al., 1985; Oud et al., 1965; Ramaekers et al., 
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1986). In this study the advantages of application of the cytokeratin 
and vimentin antibodies in 2-parameter ГСМ analysis of renal cell 
tumors have been demonstrated. First, by means of 2-parameter FCM 
analysis the cytokeratin-positive tumor cell population can be 
separated and the DNA content of the tumor cells calculated more 
precisely than without labelling. Malignant cells from RCT can be 
analysed for their DNA content, separately from stromal and 
inflammatory cells with antibodies to cytokeratin for specific 
labelling. As in the case of bladder carcinomas (Feitz et al., 19B5), 
in RCT cell suspensions containing only a low percentage of tumor 
cells the 2-parameter FCM method makes it possible to detect this 
malignant fraction and to determine its ploidy and proliferative 
capacity. The detection of tumor cells with an abnormal DNA stemline 
therefore becomes more sensitive. Second, in several cases of RCT in 
which an abnormal DNA stemline was present, a positive staining 
pattern of the tumor cells with both cytokeratin and vimentm was 
seen. Co-expression of these proteins in RCT cells is to be expected. 
The FCM data presented here thus confirm our earlier 
immunohistochemical findings (Herman et al., 19B3a). They clearly show 
that aneuploid cells (the tumor cells) of RCT contain both cytokeratin 
and vimentm. Thirdly, quantification of the different biological 
subfractions in RCT becomes possible. It remains to be evaluated 
whether or not this refinement in the classification and 
quantification of subpopulations gives more information and better 
correlation with the prognosis of the patients. 
In a comparison of 2 RCT model systems with some of the human RCT 
obtained from patients, comparable biological properties of tumor 
cells were found. First, in all xenografts as well as in the rat tumor 
model an abnormal DNA stemline was found. This tumor fraction could be 
analyzed separately from animal stromal cell components and quantified 
by the 2-parameter FCM analysis. The intermediate filament staining 
pattern found in these model tumors is therefore comparable to the 
pattern found in most primary human RCT. Co-expression of cytokeratin 
and vimentm was seen in these tumors, since aneuploid cells were 
found in both fractions and all cells which were cytokeratin- and 
vimentin-positive had about the same DNA index. 
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Therefore, the use of a combination of immunohistochemical and flow 
cytometric techniques in the investigation of complex tumors may 
provide additional information about subpopulation characteristics and 
biological potentials, independent of histological parameters. Whether 
this information can be translated into more effective prognostic 
criteria and patient management remains to be demonstrated. 
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SUMMARY 
Renal cell tumors were screened for expression of the cellular 
oncogenes c-abl, c-fes, c-fms, c-myc, с-газ and c-sis in dot blot 
hybridization analysis. Expression of c-ras and c-myc was clearly 
detectable in most of the 15 tumors that were studied. The c-fes 
oncogene appeared to be expressed in only two of them. Comparative 
Southern blot analysis of molecularly cloned human c-fes DNA and 
genomic DNA of the 15 renal tumors revealed no major genetic 
differences. Northern blot analysis of poly(A)-selected RNA from the 
fes-positive tumors with the complete viral v-fes oncogene of the 
Gardner-Arnstein strain of feline sarcoma virus as a molecular probe 
revealed hybridization of RNA species of 3.0 and 4.5 kb, 
respectively. The 3.0 kb c-fes transcript has also been reported in 
RNA from patients suffering from acute myelogenous leukemia (13). The 
4.5 kb transcript, however, has not been described before and 
represents either a c-fes-related splicing intermediate or, more 
likely, a completely processed transcript. The results of this study 
could imply that human c-fes coding sequences are more extensive than 
were previously assumed. 
KEY WORDS 
Renal cell tumors, Oncogene expression, c-fes. 
INTRODUCTION 
Based upon morphological and histochemical features, renal cell tumors 
are thought to be adenocarcinomas and to originate from the proximal 
convoluted tubule (2). In a recent study, Herman et al. (10) reported 
expression of vimentin and keratin within the same cell. These 
intermediate filament types are generally biological markers of both 
sarcomatous and carcinomatous tumors. Additional biological markers 
are required to enable further characterization of renal tumors. 
Potentially useful in this respect are the cellular oncogenes. These 
genes have been implicated in the induction of malignant 
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transformation in general and their elevated levels of expression in a 
number of human tumor cell lines as well as fresh human tumors is 
documented (13). Sometimes, malignant activation of cellular oncogenes 
seems to involve point mutations or more extensive genetic changes 
such as chromosomal rearrangements or translocations (21). In many 
tumors, cellular oncogenes such as c-H-ras, c-K-ras, c-myc and c-fos 
seem to be involved simultaneously (13). Other cellular oncogenes, 
such as for example the fes cellular oncogene, show a more restricted 
expression pattern. Expression of this cellular oncogene was mainly 
found m lung and hematopoietic malignancies and, sporadically, in 
renal tumors (13). 
To test the relevance of expression patterns of cellular oncogenes as 
markers in renal tumors, we set up a dot blot screening assay to 
determine the expression of a number of cellular oncogenes in a single 
experiment. To assess the potential implications of the expression of 
the cellular fes oncogene in renal tumors, we studied its genetic 
organization by Southern blot analysis and analyzed fes-related RNA 
transcripts by Northern blot analysis. The discovery of a new 
c-fes-related transcript is discussed. 
MATERIALS AND METHODS 
Renal Cell Tumors 
Renal cell tumors were obtained from the Department of Urology of the 
St. Radboud University Hospital. Preoperative diagnostic procedures 
including intravenous urography, selective renal arteriography, 
cavography, lung tomography, computer scanning tomography and bone 
scanning were performed. By this means, a valid T.N.M. classification 
of the tumors could be made. The renal tumors from patients including 
those with positive lymphnodes (N+) and t h o 3 e w l t h metastases (M+) 
were removed by a paramedian transabdominal radical nephrectomy. Tumor 
material was frozen in liquid nitrogen for biochemical analysis. 
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Gel Electrophoresis and Hybridization 
Restriction endonucleases were purchased from either New England 
Biolabs or Bethesda Research Laboratories (BRL) and used according to 
the specification of the manufacturers. High molecular weight DNA was 
isolated from tumor samples frozen in liquid nitrogen. Molecularly 
cloned human v-fes homologous sequences were isolated from bacterial 
strain HB101 transformed with recombinant plasmid pPH2. pPH2 is 
derivative of pSP6A containing a 12 kb EcoRI DNA insert that includes 
all human v-fes homologous sequences detectable by Southern blot 
analysis. Analysis of restriction endonuclease digested high molecular 
weight DNA from renal cell tumors was essentially as described by 
Southern (14). DNA fragments were size fractionated by electrophoresis 
through 0.8% agarose (Seakem) gels, transferred to Gene Screen Plus 
(New England Nuclear) and hybridized to ''p.^d^translated DNA 
probes. Molecular probes were nick-translated to specific activities 
of about 2-5 χ 10^ cpm/pg. Hybridization analysis was performed under 
conditions of low stringency at 42 °C for appropriate periods of time 
in 40% formamide (deiomzed, Mixed Bed Resin AG501-X8D, Biorad), 1% 
SOS, 1 M NaCl, 10% dextran sulphate and 2-5 χ 10 5 cpm/ml 
nick-translated DNA. DNA probes were labeled according to the method 
of Rigby et al. (12) using 52P-dCTP (3,000 Ci/mmole) from Amersham, 
DNAse I from Sigma and E. coli DNA polymerase I from Boehnnger. cDNA 
was labeled to high specific activity by reverse transcription of 
poly(A)-selected RNA (25 pg/ml) in 100 mM Tns-HCl (pH .З), МдСІ2 (8 
mM), NaCl (20 mM), dithiothreitol (10 mM), a mixture of dATP, dCTP, 
dGTP and dTTP (5 μΜ each), especially treated calf thymus DNA (15) 
(0.25 pg/ml) and reverse transcriptase (20 U) for 20 m m at 42 "C. 
Using 52P-dCTP, specific activities of the cDNA probes were about 1-2 
χ 10° cpm/pg. Upon hybridization, filters were washed twice in 2 χ SSC 
(1 χ SSC = 0.15 M NaCl, 0.015 M Na-citrate at room temperature for 5 
m m and twice in 2 χ SSC and 1% SDS at 50 °C for 30 m m and 
autoradiography was performed by exposing XAR-2 film (Kodak) for up to 
four days at -70 "C with Dupont lightning plus intensifying screens. 
Preparation of DNA Probes 
Characteristics of the molecular probes used in this study are 
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summarized in Table 1. DNA probes were prepared by digestion of 50-100 
pg of DNA with appropriate restriction endonucleases followed by 
electrophoresis through low melting point agarose (BRL). The desired 
bands were excised from gels and, upon melting by heating at 65 °C for 
15 m m as described (20), agarose was removed by two extractions with 
phenol, equilibrated with 10 mM Tns-HCl (pH 7.0) and 0.1 mM EDTA and 
one extraction with phenol/chloroform/isoamylalcohol (25:24:1). After 
concentration using butanol-2, DNA was precipitated in ethanol and 
0.1 M NaOAc (pH 5.2). 
Table 1: DNA fragments used as molecular probes 
Source DNA fragments Fragment used as probe Reference 
c-abl (mouse) 
c-fes (human) 
v-GA-fes (feline) 
v-fms (feline) 
c-myc (human) 
c-H-ras-1 
v-H-ras (rat) 
c-sis (human 
actin (hamster) 
feline leukemia virus 
proviral DNA 
vimentin (hamster) 
1.2 kb Pstl-PstI (cDNA) 
1.3 kb EcoRI-BglII 
3.Θ kb BGlII-HindlII 
1.45 kb Pstl-PstI 
1.2 kb EcoRI-Clal 
5.2 kb BamHI-BamHI 
0.96 kb HindlII-HindlII 
1.7 kb BamHI-BamHI 
1.2 kb Pstl-PstI (cDNA) 
5.0 kb Xhol-Xhol 
0.5 kb Pstl-PstI (cDNA) 
19 
В 
9 
5 
3 
7 
6 
18 
4 
11 
4 
RNA Isolation and Northern Blotting 
Total cellular RNA was isolated according to the lithium-urea method 
described by Auffray and Rougeon (1). Upon poly(A)-selection by 
oligo-dT-cellulose chromatography, 10 pg RNA was dissolved in sodium 
phosphate buffer (10 mM, pH 7.0), which contained DMS0 (50%) and 
glyoxal (1 M), and heated to 50 °C for one hour. RNA was size 
fractionated by agarose gel electrophoresis (1.0% agarose gel) and 
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transferred to Gene Screen Plus for hybridization analysis as 
described above. 
RESULTS 
To detect expression of the cellular oncogenes abl, fes, f ms, myc, газ 
and sis in a single experiment, a dot blot hybridisation assay was 
performed in which increasing amounts of DNA homologous to those 
cellular oncogenes were bound to Gene Screen Plus paper. Upon 
denaturation of the DNA, hybridization was performed with a '* p_cDNA 
probe synthesized in reverse transcriptase reactions with 
poly(A)-selected RNA isolated from renal cell tumors as templates. 
Synthesis of HP-cDHh was performed with random oligodeoxynucleotides 
from DNAse-digested calf thymus DNA as primer (see under Materials and 
Methods). A typical example of such a dot blot hybridization analysis 
is shown in fig. 1. A clear hybridization signal is observed in places 
where DNA is spotted homologous to v-H-ras, c-H-ras-1 and c-myc 
(human), indicating the presence of relatively high levels of related 
transcripts in this particular tumor. A weaker hybridization signal is 
observed in places where v-Ga-fes and c-fes (human) is spotted. It 
should be noted that in only 2/13 of the tumors that were tested 
expression of the cellular fes oncogene could be detected in this 
way. Expression of c-myc and c-H-ras was found in most of the 15 renal 
cell tumors that were analyzed. Transcripts homologous to the cellular 
oncogenes abl, fms and sis were not detectable in the tumors by this 
procedure. To control the assay conditions and the quality of the RNA 
preparations, actin and vimentin genes were included in the 
experiments (Fig. 1). It should be noted that the experimental 
approach does not allow the identification of the cell types that 
express the various cellular oncogenes. 
The renal cell tumor whose expression pattern of some cellular 
oncogenes is shown in Fig. 1, was obtained from a 41 year old male 
patient. The tumor waa found in the left kidney following an 
intravenous urogram indicated in the investigation of renal stone 
disease. The tumor waa staged ТгМоМо (dear cell). However, it should 
be noted that histological analysis revealed papillary structures in 
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the tumor as well as multiple intracytoplasmatic inclusions. The 
inclusions were identified by electronmicroscopy as crystalline 
protein bodies. Expression of vimentin intermediate filament protein 
was observed in an immunofluorescence study (Ramaekers, personal 
communication) which was in agreement with the hybridization data. 
Furthermore, the observation that in some cells of a renal tumor both 
vimentin and keratin were expressed, was also made in this particular 
tumor (data not shown). In a soft agar assay, the renal tumor cells 
showed no colony formation. 
Ì 
fig. 1: Analysis of expression of cellular oncogenes in renal cell 
tumor # 63 by dot blot hybridization analysis. Increasing amounts of 
DNA samples (8, 40 and 200 ng) representing molecularly cloned 
sequences of viral or cellular oncogenes were spotted onto Gene Screen 
Plus and analyzed as described in the text. DNA samples included c-abl 
(mouse) (A), c-fes (human) (B), v-fms (feline) (C), c-myc (human) (D), 
v-H-ras (rat) (E), c-H-ras-1 (human) (F), c-sis (human) (G) and 
v-GA-fes (feline) (H). Actin (hamster) (I) and vimentin (hamster) (3) 
were included as controls. As a molecular probe, Ир-сШИ synthesized 
with poly(A)-selected RNA from tumor # as template was used. 
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Fig. 2: Northern blot 
analysis of expression of 
the fes cellular oncogene 
in renal cell tumors. 
Poly(A)-selected RNA from 
tumor # 160 (lane A), 
tumor // 63 (lane B), 
normal kidney (lane C), 
tumor # 87 (lane D) and 
tumor # 148 (lane E) were 
size fractionated by 
agarose gel 
electrophoresis and 
analyzed by Northern blot 
analysis. The complete 
viral oncogene v-GA-fes 
was used as a molecular 
probe. Molecular weight 
markers included are 
single strand 
HindllI-digested Λ DNA 
fragments. 
In a further analysis of the fes expression in renal tumors, we 
studied the fes transcripts by Northern blot analysis. As a molecular 
probe, the complete viral oncogene of the Gardner-Arnstein strain of 
feline sarcoma virus was used. Two fes-related RNA species were 
detected in a poly(A)-selected RNA sample from the two renal tumors. 
Their lengths were 4.5 and 3.0 kb (Fig. 2, lanes A and В). A 
difference in the relative amounts of the two RNA species was 
observed. No fes-related RNA transcripts were detected in 
poly(A)-selected RNA samples of two other renal tumors (Fig. 2, lanes 
D and E) or from normal kidney (Fig. 2, lane C). Since the DNA probe 
contained some genetic sequences of feline leukemia virus (FeLV), 
hybridization analysis was also performed with a large portion of the 
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Fig. 3; Comparative Southern blot analysis of the с-fes locus in human 
renal cell tumors and molecularly cloned human c-fes sequences. Ten ug 
of high molecular weight DNA of normal human liver (lane A), renal 
cell tumor # 63 (lane В), tumor # 87 (lane С), tumor У/ 148 (lane D), 
tumor # 160 (lane E) and 0.5 ng of pPH2 DNA (lane F) or mixtures of 
DNA from tumor it 63 (10 ug) and pPH2 DNA (0.5 ng) (lanes G, H and I) 
were digested with restriction endonuclease EcoRI (lanes А, В, С and 
D) or combinations of EcoRI and BamHI (lane G), EcoRI and Hindlll 
(lane H) or EcoRI and Xhol (lane I), transferred to Gene Screen Plus 
and hybridized to the same molecular probe as described in the legend 
to Fig. 2. Molecular weight markers included are Hindlll-digested 
Д DNA fragments. In the lower part of the figure, a schematic 
restriction map of the human c-fes 12 kb EcoRI DNA fragment is 
depicted. B, BamHI; H, Hindlll; E, EcoRI; X, Xhol. 
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proviral DNA of FeLV as a molecular probe but not hybridization was 
observed (data not shown). 
A 3.0 kb fes-related RNA species was found in RNA isolated from 
myeloblasts of patients suffering from acute myelogenous leukemia 
(13). Our observations suggest that expression of the c-fes locus in 
renal cell tumors differs from that in acute myelogenous leukemia. To 
investigate whether or not this could be explained by chromosomal 
rearrangement, we analyzed the genetic organization of the c-fes locus 
in renal cell tumors by Southern blot analysis and compared the data 
with those obtained with molecularly cloned human c-fes DNA (Fig. 3). 
With the complete v-GA-fes oncogene as a molecular probe, all human 
v-GA-fes homologous sequences were found in a 12 kb DNA fragment in 
control human genomic DNA digested with restriction endonuclease EcoRI 
(Fig. 3, lane A). Similar analysis of genomic DNA isolated from the 15 
renal tumors revealed the same 12 kb EcoRI DNA fragment in each case 
(Fig. 3). The results of only four tumors are shown (Fig. 3, lanes B, 
C, D and E). Southern blot analysis of mixtures of genomic DNA of a 
fes-positive renal tumor (tumor # 63) and cloned human c-fes DNA 
digested with combinations of restriction endonuclease EcoRI with 
BamHI, HindiII or Xhol (Fig. 3, lanes G, H and I, respectively) did 
not reveal any differences. These results indicate that there are no 
major genetic changes in the parts of the c-fes loci in the renal 
tumors that can be detected with the complete viral v-fes oncogene as 
a probe. 
DISCUSSION 
The present study indicates that expression of the fes cellular 
oncogene occurs in some renal cell tumors and that it involves two RNA 
species of different sizes. The 3.0 kb RNA has a similar molecular 
weight as the transcript found in myeloblasts of patients with acute 
myelogenous leukemia (AML) (13). The other transcript is 4.5 kb. The 
novel appearance of a 4.5 kb fes transcription product in some renal 
tumors could be explained in different ways. The 4.5 kb RNA species is 
probably not the result of a chromosome translocation nor of other 
major chromosomal changes in the v-fea homologous region of renal cell 
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tumors since no abnormalities were seen in restriction endonuclease 
analyses of tumor DNA. A minor genetic change, on the other hand, such 
as a point mutation, a small deletion or insertion is usually not 
detected by the Southern blot analysis. It could be assumed that such 
a minor genetic change would affect the processing of c-fes pre-mRNA 
in such a way that two different products are being formed from one 
gene. In that case, it may be that one particular step in the splicing 
process is limited in renal tumors since no other fes-related splicing 
intermediates were detected. Differential gene splicing is a well 
documented phenomenon in tumor viruses. There is no reason why this 
mechanism might be limited to viral genes. 
Alternatively, the new transcript could be due to a secondary mutation 
in a tumor cell which grew out to a subpopulation of cells within the 
tumor. Finally, the possibility that both RNAs constitute independent 
and naturally occurring transcripts cannot be excluded. Clearly, more 
experimental work is needed to discriminate between these 
explanations. 
While the 3.0 kb transcript is approximately of the same size as the 
viral gene, v-fes, used as a molecular probe in these studies, the 
newly discovered occurrence of a 4.5 kb transcript in two different 
tumors raises the possibility that the human c-fes locus is larger 
than the 12 kb EcoRI restriction endonuclease fragment that contains 
all sequences homologous to v-fes. It is accepted that the retroviral 
oncogenes which have been generated in a process in which RNA tumor 
viruses have captured cellular genetic sequences from their natural 
hosts, often represent only a portion of the cellular locus (9, 19). 
It is , therefore, possible that the v-fes oncogene of the 
Gardner-Arnstein strain of feline sarcoma virus encodes only the 
tyrosine-specific protein kinase domain of a more complex protein and 
that parts of the cellular locus involved are not represented in any 
of the other fes-related viral oncogenes. The epidermal growth factor 
receptor (17) and the insulin receptor (16) are examples of such 
complex proteins with a tyrosine-specific protein kinase domain as an 
intrinsic structural component. The 4.5 kb fes-related RNA species 
could represent a transcript of a larger yet to be defined c-fes 
locus. Further studies are required to resolve this matter. 
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SUMMARY AND CONCLUSIONS 
Chapter I represents a review of literature on renal cell carcinoma to 
put the issues of this thesis in the right context. Up until this 
moment no consistant therapeutical approach exists for metastasized 
renal cell carcinoma in man. Une of the methods to achieve a 
progression in the treatment of this disease is to obtain a better 
understanding of biological and biochemical aspects of the tumor. For 
this purpose a spontaneous rat renal cell carcinoma, several human 
renal cell carcinoma xenografts in nude mice and primary human renal 
cell tumors were studied and compared. In order to give an 
introduction on renal cell carcinoma an inventory is made on 
epidemiology, clinical presentation and metastatic behaviour. Also 
features of possible prognostic value as identifiable by macroscopic, 
microscopic and ultrastructural evaluation are surveyed. Eventually 
recent developments in the characterization of tumor cells, applied 
and studied in this thesis, are described as there are intermediate 
filament studies, flow cytometric cellular DNA content measurement and 
activated oncogene determination. 
In chapter II a tumor model system, derived from a spontaneously 
arosen renal cell carcinoma of a Whistar Lewis rat is characterized in 
a multidisciplinary way and compared to human renal cell carcinoma. It 
is shown that a great resemblance of histological and ultrastructural 
features exist. Also the expression of intermediate filaments (i.e. 
coexpression of vimentin and cytokeratin) and results of DNA 
measurements in flow cytometric double labeling experiments are 
comparable to what is encountered in primary human renal cell 
carcinomas. In addition, increased levels of vimentin mRNA were 
found. A positive growth capacity in the double layer soft agar human 
tumor cloning system was evident. It is concluded that this tumor 
model has several histological and biological properties in common 
with the human renal cell tumor and that it is a suitable model for 
studying new cytotoxic drugs. 
Chapter III describes an analogous study performed on four human renal 
cell carcinoma xenografts maintained in nude mice. The results showed 
that these four tumor lines contained a variety of histological, 
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histochemical and biochemical properties that also occur in the 
primary human tumor. It became clear, however, that also marked 
differences in character between the different xenografts existed, 
demonstrating the heterogeneity of renal cell carcinoma. Such 
xenografts, representing different subtypes of renal cell carcinoma, 
may prove to be of great value in in vitro screening of effects of new 
Chemotherapeutics. 
In chapter IV the activated oncogene expression in several xenografts 
and a monkey kidney cell line is studied. The oncogene analysis was 
performed by Northern blot technique. It was found that all xenografts 
expressed c-ras. Expression of c-myc or the p53 gene was found in all 
xenograts but one. Interestingly c-fes/fps mRNA was elevated in all 
tumors in contrast to what is seen in primary human renal cell 
carcinomas, where c-fes/fps expression is only present in 10-20% of 
the cases. The possible explanations were discussed. Furthermore it 
was concluded that the xenograft tumor model system is very useful in 
oncogene expression studies as it is capable to provide consistant 
high amounts of mRNA. As far as molecular oncology is concerned, the 
xenografts are easy to handle and oncogene expression is comparable to 
what is reported in literature about human renal cell carcinomas and 
to our own results in primary renal cell tumor oncogene analysis 
(chapter VI). 
Chapter V describes the use of cytokeratin and vimentin as tissue 
specific markers in histochemical and flow cytometric double labeling 
studies of primary renal cell carcinomas, a tumor metastasis and 
several tumor model systems. The different cell populations that could 
be identified by immunohistochemical staining, could also separately 
be analysed for their DNA content. This was done by a double labeling 
flow cytometric technique. With this method also a coexpression of 
vimentin and cytokeratin was detected in the aneuploid tumor cell 
population. It was shown that renal cell tumor model systems could, in 
this regard, be compared to primary renal cell tumors. 
In chapter VI an analysis of the oncogene expression in 15 primary 
renal cell carcinomas with dot blot technique is described. An 
expression of c-ras and c-myc was clearly detectable in most of these 
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tumors. In two cases an additional oncogene, c-fea, which is known to 
have a tyrosine specific kinase activity, was found to be expressed. 
Northern blot analysis revealed two mRNA species, one of 3.0 kb and 
one of 4.3 kb. Southern blot techniques were performed to check the 
structure of the c-fes locus but no major changes could be found in 
its genetic organization. 
Reviewing the experimental chapters of this thesis, two questions 
arise. Firstly, what is the value of these tumor model systems in 
relation to the research for more successfull approaches in the 
treatment of renal cell carcinoma? Secondly, which direction the 
further development of the research needs to follow. 
As far as the tumor model systems concerned, a division is to be made 
between the rat renal cell tumor and the xenografts. The rat tumor 
line is the more easy évaluable model system. It is easily maintained 
in different generations of rats and appears to be histologically and 
biologically stable. As a result of this, one is able to conduct well 
designed and reproducable studies. However, as it concerns a pure 
animal model, there remains uncertainty about the direct applicability 
of the experimental results to the human renal cell carcinoma, taking 
in account that the renal cell carcinoma is a very complex tumor, 
presenting a great variability of characteristics and behaviour 
(chapter I). 
The xenografts offer a different problem. In these cases it concerns 
original human tumors, from which a stable tumor line was established 
in the nude mouse. These xenografts often appear to have a very 
specific character. Also one has to realize that a certain xenograft 
is developed from only a small part of the primary tumor, which is the 
part of the tumor that possesses the potential of growth in a host 
animal. In addition it is very well possible, that cells with certain 
specific biochemical features are furthermore selected by the process 
of transplantation. The latter is suggested by the results of the 
oncogene analyses of several xenografts (chapter IV). In the 
interpretation of results obtained in xenografts one should always 
keep in mind that this xenograft only represents a part of the 
original tumor and also the suggested positive selection for new 
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characteristics during further transplantations may have a decisive 
influence on the outcome of experiments. Furthermore it became clear 
from the study of xenografts that certain features suggesting an 
aggressive tumor character in vivo, as there are histological 
dedifferentiation and a high degree of aneuploidy, do not necessarily 
lead to a greater growth potential in vitro (RC43, chapter III). 
Finally one should consider the fact that in this model a human tumor 
is maintained against a totally different biological background 
compared to the original tumor. The nude mouse is not only 
immunologically deficient, but also all species specific interactions 
between tumor and host are not present. 
If one takes the special demands for an animal laboratory in account 
necessary for maintaining nude mice, one must come to the conclusion 
that establishing xenografts is a relatively expensive method, in 
which a model system is obtained, undoubtedly superior to an animal 
model, but with certain clear restrictions. 
So, the strategy has to be, that one uses the model for its better 
experimental accessibility compared to the primary tumor, but that the 
relevance of the results always should be checked on the original 
carcinoma. 
In answer to the question in which direction the research of the renal 
cell carcinoma should be pointed, it is obvious that the answer has to 
be found in the solution of the structure and functional mechanisms of 
the gene systems involved in the origin of this form of cancer. 
The molecular biological results described in this thesis must be seen 
in the light of a breakthrough in genetics at this moment, as a result 
of the DNA recombination technology. Nowadays a great variety of DNA 
research is performed, both with a scientific and with a commercial 
goal. Many smaller or bigger progressions are made in this field, 
resulting in new biological concepts, for instance in carcinogenesis. 
In this light our data must be regarded as a small part of a hughe 
molecular oncological research program. Also one has to realize that 
the renal cell carcinoma is only one of the many malignancies, that as 
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a result of its specific characteristics (as any other tumor) can only 
contribute modestly to the total understanding of carcinogenesis. 
There are some hundred different tumors identified in humans (the 
exact amount depends of course on the method used for their 
catalogization). They all have their individual advantages and 
disadvantages in experimental research. 
The renal cell carcinoma generally concerns a tumor well fit for DNA 
and RNA studies because of its generally large volume, which makes it 
possible to retrieve a sufficient amount of tissue without endangering 
the histological diagnosis. A disadvantage of the primary renal cell 
tumor as a molecular biological study object, is that as a result of 
the relatively long time elapsing between devitalisation of the tumor 
by clamping the renal vessels during the operation and the moment of 
fixation by freezing it in liquid nitrogen, the quality of RNA worsens 
quickly. 
Another difficulty is that in certain cases the results of the 
analyses can be influenced by the fact that the tumor is not 
homogenous as a result of marked préexistent necrosis. 
As mentioned in the introduction of this thesis there are two 
mechanisms by which oncogenes can contribute to the deregulation of 
the cell. Besides a raised transcription activity of a basically 
normal proto-oncogene, also a structural change in the gene can lead 
to a modified gene product, resulting in a changed cellular fenotype. 
Also our molecular biological analyses reveal twofold results. 
Firstly an insight is obtained in which of the oncogenes and groups of 
oncogenes are activated in the renal cell carcinoma and some of its 
model systems. The findings appear to support the hypothesis of the 
multiple step principle in carcinogenesis and also show that the renal 
cell carcinoma is grossly comparable to many other tumors in this 
respect. 
Secondly, the expression of a specific oncogen, c-fes, was studied. 
Abnormal fes mRNA species were found in the renal cell carcinoma and 
in addition c-fes appears to be expressed in almost all xenografts, in 
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contrast to what is found in primary renal cell carcinoma (chapter IV 
and VI). These findings have already led to a further research progran 
on c-fes. 
In conclusion, the experimental results of this thesis constitute a 
first step towards an extensive research program, which can 
eventually, by a team of researchers during many years, lead to a 
substantial contribution to the knowledge of the origin and 
development of cancer. 
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SAMENVATTING EN CONCLUSIES 
In hoofdstuk I wordt een overzicht van de literatuur over het 
mercelcarcinoom gegeven met het doel de onderzoekingen, zoals deze 
worden beschreven in dit proefschrift, in hun juiste context te 
plaatsen. Tot op dit moment bestaat er geen eenduidige therapeutische 
benadering voor het gemetastaseerd mercelcarcinoom in de mens. Een 
van de wijzen om vooruitgang te boeken in de behandeling van deze 
ziekte, is te trachten een beter inzicht te verkrijgen in de 
biologische en biochemische aspecten van deze tumor. Met dit doel voor 
ogen worden een spontaan in een rat ontstane niertumor, verschillende 
xenografts van het humane mercarcinoom in de naakte muis naast 
primaire menselijke niertumoren bestudeerd en vergeleken. Hoofdstuk I 
geeft een introductie omtrent het mercarcinoom aan de hand van een 
overzicht van de epidemiologie en het klinische gedrag. Verder worden 
mogelijke prognostische factoren besproken. Tenslotte worden nieuwe 
onderzoeksmethoden waaronder intermediaire filamentenstudies, DNA-
metingen met behulp van flowcytometne en studies van geactiveerde 
oncogenen nader toegelicht. 
In hoofdstuk II wordt in een multidisciplinaire benadering een 
tumormodelsysteem, dat afkomstig is van een spontaan ontstaan 
mercelcarcinoom in een Wistar Lewis rat gekarakteriseerd en 
vergeleken met het primaire menselijke mercelcarcinoom. Er wordt 
aangetoond dat een grote gelijkenis voorhanden is op zowel 
histologisch als electronerwucroscopisch gebied. Ook de expressie van 
intermediaire filamenten (i.e. co-expressie van vimentine en 
cytokeratine) en de resultaten van DNA-metingen in flowcytometnsche 
dubbellabeling experimenten blijken vergelijkbaar te zijn met hetgeen 
men vindt in de primaire menselijke niercelcarcinomen. Daarenboven 
wordt een verhoogd expressie niveau van vimentine mRNA gevonden. Een 
positieve groeicapaciteit in het HTCS (human tumor cloning system) is 
duidelijk. De conclusie luidt dat dit tumormodel verschillende 
histologische en biologische eigenschappen gemeen heeft met het humane 
mercelcarcinoom en dat het een geschikt model is voor onder andere de 
studie van nieuwe cytotoxische medicamenten. 
Hoofdstuk III beschrijft een gelijkaardige studie, uitgevoerd aan de 
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hand van vier xenografts van primaire humane niercelcarcinomen. De 
resultaten geven aan dat deze vier tumorlijnen een onderling zeer 
gevarieerd profiel ten aanzien van histologische, histochemische en 
biochemische eigenschappen ten toon spreiden, waarvan de diverse 
elementen ook in het primaire niercarcinoom voorkomen. Het is 
duidelijk dat er ook een aanzienlijk verschil in karakter tussen de 
onderlinge xenografts bestaat, waarmee tevens de heterogemciteit van 
het niercelcarcinoom wordt aangetoond. Als zodanig kunnen xenografts, 
wanneer zij beschouwd worden als vertegenwoordigers van de 
verschillende subtypes van het niercelcarcinoom, van grote waarde 
blijken te zijn bij in vitro screening van de effecten van nieuwe 
chemotherapeutica. 
In hoofdstuk IV wordt de geactiveerde oncogen expressie van 
verschillende xenografts en een apemercellijn bestudeerd. De 
oncogeenanalyse wordt uitgevoerd aan de hand van Northern blot 
techniek. Als resultaat wordt gevonden dat alle xenografts c-ras 
expressie vertonen. Expressie van c-myc of van het p53 gen werd 
gevonden in alle xenografts op één na. Interessant is het gegeven dat 
c-fes/fps mRNA verhoogd was in alle tumoren, in tegenstelling tot wat 
bij primaire humane niercelcarcinomen wordt gevonden, waar c-fes/fps 
expressie slechts aanwezig is in 10-20% van de gevallen. De mogelijke 
verklaring hebben wij bediscussieerd. Verder wordt geconcludeerd dat 
de xenograft tumor model systemen zeer nuttig zijn bij oncogen 
expressiestudies van het niercarcinoom, aangezien het door de 
homogeniteit van de tumor mogelijk is aanzienlijke hoeveelheden mRNA 
te isoleren. In het kader van de moleculaire oncologie zijn de 
xenografts goed te bewerken tumorsystemen en de oncogen expressie 
lijkt vergelijkbaar met hetgeen bekend is over het primaire menselijke 
niercelcarcinoom. 
Hoofdstuk V beschrijft het gebruik van cytokeratine en vimentine als 
weefselspecifieke markers bij histochemische en flowcytometrische 
studies van het primaire niercarcinoom, een tumormetastase en 
verschillende tumormodelsystemen. De verschillende celpopulaties die 
kunnen worden geindentificeerd door immunohistochemische kleuring, 
kunnen ook afzonderlijk worden geanalyseerd wat betreft hun DNA-inhoud 
aan de hand van de flowcytometne met het gebruik van twee 
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verschillende kleurlabels. Met behulp van deze methode werd ook een 
co-expressie van vimentine en cytokeratine aangetoond in aneuploide 
tumorcelpopulaties. Het was duidelijk dat niercel tumor model systemen 
in dit opzicht vergeleken kunnen worden met het primaire 
niercelcarcinoom. 
In hoofdstuk VI wordt de analyse beschreven van de oncogen expressie 
in 15 primaire niercelcarcmomen aan de hand van dot blot techniek. 
Een expressie van c-ras en c-myc is duidelijk aantoonbaar in de meeste 
van deze tumoren. In twee gevallen blijkt een additioneel oncogeen, 
c-fes, waarvan bekend is dat het een tyrosine specifieke kinase 
activiteit heeft, tot expressie te komen. Northern blot analyse bracht 
twee mRNA soorten aan het licht, een van 3.0 kb en een van 4.5 kb. 
Southern blot technieken werden uitgevoerd om de structuur van het 
c-fes locus te analyseren. Hierbij konden geen veranderingen van enig 
belang in de genetische organisatie gevonden worden. 
Wanneer men de experimentele hoofdstukken van dit proefschrift 
overziet, dringen zich twee vragen op. Ten eerste, wat is de waarde 
van deze tumormodelsystemen bij het onderzoek van het menselijk 
mercarcinoom. En ten tweede, in welke richting moet de ontwikkeling 
van de research t.a.v. de niertumor verder gaan. 
Ten aanzien van de tumormodelsystemen dient een onderscheid gemaakt te 
worden tussen het rattemodel en de xenografts. De rattetumorlijn is 
het meest eenvoudig te bestuderen modelsysteem. Het is vrij 
gemakkelijk te handhaven in opeenvolgende generaties ratten en blijkt 
daarbij histologisch en biologisch stabiel te zijn. Door dit gegeven 
wordt men in staat gesteld weloverwogen en reproduceerbare 
experimenten uit te voeren. Echter, omdat dit model een zuiver 
diermodel is, bestaat er onzekerheid in hoeverre men de experimentele 
resultaten mag projecteren op het menselijk mercarcinoom. Te meer 
omdat het mercarcinoom bij de mens een zeer complexe tumor is met een 
zeer variabel beloop (hoofdstuk I). 
Enigszins anders ligt het met betrekking tot de xenografts. Hierbij 
betreft het oorspronkelijke menselijke tumoren, waaruit een stabiele 
tumorlijn in naakte muizen tot stand is gebracht. Deze xenografts 
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blijken vaak een geheel eigen karakter te bezitten, dat onderling 
nogal kan verschillen. Daarnaast dient men zich te realiseren dat een 
dergelijke xenograft ontstaat uit slechts een deel van de primaire 
tumoren, en wel dat deel dat de potentiële eigenschap van groei in een 
gastheer bezit. Daarbij is het heel goed mogelijk, dat er een verdere 
selectie ontstaat voor cellen met bepaalde specifieke biochemische 
karakteristieken, die bijdragen tot een groter percentage succesvol 
overgezette cellen tijdens verdere transplantaties. Dit aspect wordt 
althans gesuggereerd door de resultaten van oncogeenanalyses van de 
diverse xenografts (hoofdstuk IV). Men mag bij de interpretatie van 
resultaten met verhelen, dat een xenograft waarschijnlijk slechts een 
deel van de oorspronkelijke tumor vertegenwoordigt. Daarenboven draagt 
de veronderstelde positieve selectie voor nieuwe eigenschappen tijdens 
verdere transplantaties er toe bij dat de resultaten van experimenten 
wezenlijk beïnvloed kunnen worden. Ook is uit de bestudering van 
xenografts duidelijk geworden, dat kenmerken van een tumor, die wijzen 
op een agressief gedrag in vivo, zoals bijvoorbeeld histologische 
dedifferentiatie van cellen of een hoge mate van aneuploidie, 
geensziens hoeven te leiden tot een groter groeipotentieel in vitro 
(RC43, hoofdstuk III). Tenslotte moet nog genoemd worden de 
vanzelfsprekende beperking, dat in dit modelsysteem sprake is van de 
groei van een menselijke tumor in een totaal verschillend biologisch 
milieu in vergelijking met de primaire tumor. Niet alleen is de naakte 
muis immunologisch kreupel, maar ook alle species-specifieke 
interacties tussen de gastheer en de tumor ontbreken. 
Wanneer men in overweging neemt dat er speciale eisen dienen te worden 
gesteld aan een dierenlaboratorium alleen al om met naakte muizen te 
kunnen werken, is de studie van xenografts een naar verhouding dure 
methodiek. Men verkrijgt echter een modelsysteem dat ondanks de 
genoemde beperkingen, ongetwijfeld superieur is aan een diermodel. De 
strategie moet dus zijn dit model te gebruiken voor een betere 
experimentele toegankelijkheid dan de primaire tumor, maar de 
relevantie van de gevonden resultaten dient steeds aan het authentieke 
carcinoom getoetst te worden. 
Op de vraag in welke richting de research van het mercarcinoom en van 
de carcinogenese in het algemeen zich zou moeten ontwikkelen, is het 
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voor de hand liggend dat het antwoord gezocht moet worden in de 
opheldering van de structuur en het functionele mechanisme van de 
gensystemen betrokken bij het ontstaan van deze vorm van kanker. 
De bevindingen in dit proefschrift op moleculair oncologisch gebied 
moeten gezien worden in het licht van een doorbraak in de genetica op 
dit moment, als gevolg van de recombinant DNA technologie. 
Hedentendage wordt op velerlei manieren aan DNA onderzoek gedaan, 
zowel met een wetenschappelijk als een commercieel oogmerk. Op vele 
fronten tegelijk wordt vooruitgang geboekt, die bijdraagt tot nieuwe 
biologische concepten, o.a. op het terrein van de oncologie. 
Onze waarnemingen kunnen dan ook niet anders gezien worden dan als een 
klein onderdeel van een omvangrijk moleculair oncologisch onderzoek. 
Ook moet men zich realiseren dat het niercarcinoom slechts een van de 
vele tumoren is, dat door zijn specifiek karakter evenals elke andere 
tumor, maar een klein deel zal kunnen bijdragen tot het totaal begrip 
van het ontstaan van kanker. 
Er zijn ongeveer honderd verschillende tumoren bekend bij de mens (het 
precieze aantal is uiteraard afhankelijk van de indeling die men 
maakt). Zij hebben allen hun voor- en nadelen bij experimenteel 
onderzoek. Het niercarcioom betreft een tumor, die door zijn over het 
algemeen aanzienlijk omvang geschikt is voor het aanleveren van 
voldoende weefsel voor DNA en RNA bewerking, zonder dat hierdoor de 
histologische diagnostiek gevaar loopt. Een nadeel van de primaire 
niertumor als moleculair oncologisch studie-object, is dat door de 
vrij lange tijdsspanne tussen het moment van devitalisering van de 
tumor op het moment van afklemmen van de mervaten tijdens de operatie 
en het moment van invriezen in vloeibare stikstof, de kwaliteit van 
met name RNA sterk achteruitloopt. 
Een tweede moeilijkheid is het feit dat een niertumor, evenals vele 
andere tumoren, macroscopisch meestal heterogeen is, mede doordat vaak 
een aanzienlijke necrose in het preparaat aanwezig is. Dit zou in 
bepaalde gevallen de resultaten van de analyses kunnen vertroebelen, 
omdat de gevonden gegevens maar op een deel van de totale tumor 
betrekking hebben. 
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Zoals in de inleiding van dit proefschrift vermeld wordt, zijn er in 
grote lijnen twee mechanismen waardoor oncogenen kunnen bijdragen tot 
de deregulatie van de cel. Naast het feit dat dit kan bestaan uit een 
verhoogde transcriptie activiteit van een op zichzelf normaal 
proto-oncogen, kan ook door structurele verandering in het gen een 
gemodificeerd genproduct ontstaan, met gevolgen voor het fenotype van 
de cel. Aldus blijkt dat ook onze moleculair biologische analyses 
tweeërlei resultaten hebben opgeleverd. 
Eerstens is er een inzicht verkregen in welke van de belangrijkste 
oncogenen en oncogencategorieën er geactiveerd zijn in het 
niercarcinoom en enkele van zijn modelsystemen. De bevindingen blijken 
daarbij een ondersteuning te vormen voor de hypothese van het 
meertrapsprincipe van de carcinogenese en geven bovendien aan dat het 
niercarcinoom in dit opzicht afgezien van enige details in grote 
lijnen niet afwijkt van vele andere tumoren. 
Het tweede aspect van onze analyses betreft de bestudering van de 
expressie van een specifiek oncogen, namelijk c-fes. Er zijn abnormale 
fes mRNA species aangetroffen in het niercarcinoom en daarenboven 
blijkt c-fes in vrijwel alle xenografts tot expressie te komen in 
tegenstelling tot hetgeen het geval is bij primaire niertumoren, waar 
deze expressie slechts zelden voorkomt (hoofdstuk IV en VI). 
In het licht van deze bevindingen is inmiddels een verder 
onderzoeksprogramma voor dit c-fes oncogen opgezet. 
Samenvattend concluderen wij dat de experimentele resultaten van dit 
werk een eerste stap zijn in een uitvoeriger programma, dat door een 
team van onderzoekers gedurende een reeks van jaren kan leiden tot een 
wezenlijke bijdrage in het inzicht in het ontstaan en de ontwikkeling 
van kanker. 
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STELLINGEN BEHORENDE BIJ HET PROEFSCHRIFT: 
A CO№ARATIVE STUDY OF RENAL CELL TUMOR MODEL SYSTEMS. 
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1. De radicale nefrectomie voor een beperkt niercarcinoom, waarbij 
men eerst de vaatsteel onderbindt, heeft een gunstig effect op de 
prognose van de gastheer, maar reduceert de mogelijkheden tot 
moleculair oncologisch onderzoek van zijn tumor. 
2. De benaming niercelcarcinoom roept een beeld van uniformiteit op, 
dat echter wordt tegengesproken door de gebleken diversiteit van 
de karakterprofielen van de verschillende xenografts van het 
niercelcarcinoom in de naakte muis. 
3. Succesvolle transplantatie van niercarcinomen in de vorm van een 
xenograft vraagt aanpassingsvermogen van de tumor. 
4. Schematische behandeling van kwaadaardige gezwellen is de 
belangrijkste bijdrage, die de clinicus kan leveren aan een groter 
begrip van het gedrag van deze tumor. 
5. Hoewel klinische onderzoekstrials veelal als academische 
liefhebberij worden gezien, dienen perifere specialisten zich te 
realiseren dat zij door met name hun kwantitatieve inbreng deze 
trials tot werkelijk zinvolle toetsstenen kunnen verheffen. 
6. De belangrijkste bijdragen tot een verbeterde vijfjaara overleving 
van het coloncarcinoom worden geleverd door de afname van de 
perioperatieve sterfte en de toename van het percentage tumoren 
dat gereseceerd wordt. 
(Proefschrift T. Wiggers, Maastricht 1987) 
7. De samenwerking tussen clinicus en experimenteel onderzoeker kan 
slechts dan succesvol zijn, wanneer zij begrip weten op te brengen 
voor de specifieke problemen van eikaars vakgebied. 
8. De onontkoombare prioriteitenkeuze in de academische ziekenhuizen 
als gevolg van budgetteringsmaatregelen noopt de opleiders van met 
name de snijdende specialismen tot een kritische beschouwing van 
de door hen gegeven opleiding. 
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9. Op basis van immunohistochemische detectie van antilichamen die 
geassocieerd zijn met normaal darmepitheel, kunnen patiënten met 
een morfologisch identieke colontumor worden ingedeeld in 
categorieën met een verschillende prognose ten aanzien van deze 
tumor. 
(Proefschrift T. Wiggers, Maastricht 1987) 
10. Bij de cursussen voor zei f af richting van honden komt men veelal 
meer aan de weet over het karakter van de baas dan dat van zijn 
hond. 
11. De combinatie van conventionele anaesthesie en acupunctuur 
vermindert de behoefte aan het peroperatief gebruik van opiaten. 
12. Bij de voetjacht op het haas met een meute Bassethonden, heeft 
lampe juist op het moment dat hij uitgeput dreigt te raken de 
grootste kans om vrij uit te gaan. 
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